

Interim financial information

1st Quarter of 2023

(Convenience Translation into English from the
Original Previously Issued in Portuguese)

Oncoclínicas do Brasil Serviços Médicos S.A.

Individual and Consolidated
Interim Financial Information for the
Quarter Ended March 31, 2023 and
Independent Auditor's Report

Deloitte Touche Tohmatsu Auditores Independentes Ltda.

(Convenience Translation into English from the Original Previously Issued in Portuguese)

REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION

To the Shareholders, Directors and Management of
Oncoclínicas do Brasil Serviços Médicos S.A.

Introduction

We have reviewed the accompanying individual and consolidated interim financial information of Oncoclínicas do Brasil Serviços Médicos S.A. ("Company"), included in the Interim Financial Information Form (ITR) for the quarter ended March 31, 2023, which comprises the individual and consolidated balance sheets as at March 31, 2023, and the related individual and consolidated statements of profit and loss, of comprehensive income, of changes in equity and of cash flows for the three-month period then ended, including the explanatory notes.

The Executive Board is responsible for the preparation of this individual and consolidated interim financial information in accordance with technical pronouncement CPC 21 (R1) and international standard IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board - IASB, as well as for the presentation of such information in accordance with the standards issued by the Brazilian Securities and Exchange Commission (CVM), applicable to the preparation of Interim Financial Information (ITR). Our responsibility is to express a conclusion on this interim financial information based on our review.

Scope of review

We conducted our review in accordance with Brazilian and international standards on review of interim financial information (NBC TR 2410 and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the standards on auditing and, consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion on the individual and consolidated interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the individual and consolidated interim financial information included in the ITR referred to above was not prepared, in all material respects, in accordance with technical pronouncement CPC 21 (R1) and international standard IAS 34, applicable to the preparation of ITR, and presented in accordance with the standards issued by the CVM.


Other matters

Statements of value added

The individual and consolidated interim financial information referred to above includes the individual and consolidated statements of value added (DVA) for the three-month period ended March 31, 2023, prepared under the responsibility of the Company's Executive Board and presented as supplemental information for international standard IAS 34 purposes. These statements were subject to the review procedures performed together with the review of the Interim Financial Information (ITR) to reach a conclusion on whether they are reconciled with the interim financial information and the accounting records, as applicable, and if their form and content are consistent with the criteria set forth in technical pronouncement CPC 09 - Statement of Value Added. Based on our review, nothing has come to our attention that causes us to believe that these statements of value added were not prepared, in all material respects, in accordance with the criteria defined in such standard and consistently with the individual and consolidated interim financial information taken as a whole.

The accompanying individual and consolidated interim financial information has been translated into English for the convenience of readers outside Brazil.

Belo Horizonte, May 15, 2023


DELOITTE TOUCHE TOHMATSU
Auditores Independentes Ltda.


Daniel de Carvalho Primo
Engagement Partner

ONCOCLÍNICAS DO BRASIL SERVICOS MÉDICOS S.A.

BALANCE SHEETS AS OF MARCH 31, 2023 AND DECEMBER 31, 2022
(In thousands of reais – R\$)

ASSETS	Note	Parent Company		Consolidated		LIABILITIES AND SHAREHOLDERS' EQUITY	Note	Parent Company		Consolidated	
		03/31/2023	12/31/2022	03/31/2023	12/31/2022			03/31/2023	12/31/2022	03/31/2023	12/31/2022
CURRENT ASSETS						CURRENT LIABILITIES					
Cash and cash equivalents	5	52.659	79.931	409.757	263.208	Suppliers	15	34.533	50.589	531.273	604.785
Securities and financial assets	6	121.233	593.351	360.857	829.594	Suppliers - drawee risk	16	-	-	-	183.781
Derivative financial instruments	17	2.024	-	2.024	-	Loans and financing	17	18.695	22.316	367.761	321.580
Trade accounts receivable	7	36.118	33.262	1.631.445	1.379.614	Derivative financial instruments	17	-	10.113	631	11.142
Inventories	8	16.651	17.060	151.444	163.937	Debentures	18	35.608	7.771	60.177	17.245
Recoverable taxes	9	54.930	52.962	167.148	142.602	Social charges	19	26.594	39.267	94.662	100.574
Dividends receivable	31.2	41.420	41.420	-	-	Tax liabilities	20	8.993	7.830	115.302	100.249
Other assets	10	24.276	21.602	56.285	47.874	Income tax and social contribution payable		-	-	9.137	4.548
Total current assets		<u>349.311</u>	<u>839.588</u>	<u>2.778.960</u>	<u>2.826.829</u>	Accounts payable for acquisitions	21	18.081	1.620	177.424	301.067
						Dividends payable	31.5	-	-	46.432	47.091
						Lease liabilities	14.2	5.655	4.885	81.490	64.170
						Other liabilities	22	<u>52.351</u>	<u>53.960</u>	<u>144.764</u>	<u>127.047</u>
NON-CURRENT ASSETS						NON-CURRENT LIABILITIES					
Securities and financial assets	6	765	765	12.050	12.144	Total current liabilities		<u>200.510</u>	<u>198.351</u>	<u>1.629.053</u>	<u>1.883.279</u>
Judicial deposits	23	7.565	7.578	19.443	18.422						
Deferred income tax and social contribution	29.c	-	-	250.691	223.428						
Related parties	31.1	489.098	191.905	35.243	32.311	Loans and financing	17	535.668	537.305	1.328.192	1.038.599
Advances for future capital increase	31.3	94.278	349.803	-	-	Debentures	18	739.048	738.489	1.731.503	1.727.918
Other assets	10	22.604	22.568	79.311	79.354	Social charges	19	1.327	776	1.327	776
						Tax liabilities	20	-	-	14.569	15.125
						Deferred income tax and social contribution		-	-	6.660	6.385
Investments in subsidiaries and associated companies	11	2.730.184	2.425.124	23.482	22.222	Provision for tax, labor and civil risks	23	26	82	60.478	61.618
Property, plant and equipment	12	55.612	56.073	718.886	706.783	Accounts payable for acquisitions	21	88.415	102.328	589.762	468.800
Intangible assets	13	261.651	257.431	3.979.820	3.914.464	Related parties	31.4	354.586	380.455	3.337	2.570
Right-of-use	14.1	12.171	12.363	369.371	383.822	Advances for future capital increase	31.6	-	-	6.351	6.351
Total non-current assets		<u>3.673.928</u>	<u>3.323.610</u>	<u>5.488.297</u>	<u>5.392.950</u>	Lease liabilities	14.2	8.564	9.105	276.903	304.660
						Provision for loss on investment in subsidiaries	11	25.464	27.055	-	-
						Other liabilities	22	<u>47.592</u>	<u>51.467</u>	<u>69.639</u>	<u>71.242</u>
						Total non-current liabilities		<u>1.800.690</u>	<u>1.847.062</u>	<u>4.088.721</u>	<u>3.704.044</u>
SHAREHOLDERS' EQUITY						SHAREHOLDERS' EQUITY					
						Capital	24	2.249.716	2.249.716	2.249.716	2.249.716
						Expenditures with public offering of shares		(104.466)	(104.466)	(104.466)	(104.466)
						Treasury shares		(93.453)	(79.396)	(93.453)	(79.396)
						Capital reserve		812.645	805.276	812.645	805.276
						Equity valuation adjustment		14.120	13.361	14.120	13.361
						Transaction among partners		(590.215)	(478.214)	(590.215)	(478.214)
						Accumulated losses		(266.308)	(288.492)	(266.308)	(288.492)
						Shareholders' equity attributed to non-controlling interest					
						parent company's shareholders		2.022.039	2.117.785	2.022.039	2.117.785
						Non-controlling shareholders		-	-	527.444	514.671
						Total shareholders' equity		<u>2.022.039</u>	<u>2.117.785</u>	<u>2.549.483</u>	<u>2.632.456</u>
TOTAL ASSETS		<u>4.023.239</u>	<u>4.163.198</u>	<u>8.267.257</u>	<u>8.219.779</u>	TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		<u>4.023.239</u>	<u>4.163.198</u>	<u>8.267.257</u>	<u>8.219.779</u>

See the accompanying notes to the financial statements

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

STATEMENTS OF INCOME
FOR THE YEARS ENDED MARCH 31, 2023 AND MARCH 31, 2022
(In thousands of reais - R\$, except loss per share)

	Note	Parent Company		Consolidated	
		01/01/2023– 3/31/2023	01/01/2022– 03/31/2022	01/01/2023– 03/31/2023	01/01/2022– 03/31/2022
NET REVENUE	25	54.802	44.522	1.293.459	807.952
Cost of services rendered	26	(38.973)	(32.205)	(822.914)	(536.621)
GROSS INCOME		<u>15.829</u>	<u>12.317</u>	<u>470.545</u>	<u>271.331</u>
OPERATING REVENUES (EXPENSES)					
General and administrative expenses	26	(22.637)	(28.790)	(271.237)	(200.404)
Other operating revenues (expenses), net	26	315	683	9.340	1.644
Equity in net income of subsidiaries	11	73.789	(14.074)	97	-
OPERATING INCOME (LOSS) BEFORE FINANCIAL INCOME		<u>67.296</u>	<u>(29.864)</u>	<u>208.745</u>	<u>72.571</u>
FINANCIAL INCOME (LOSS)					
Financial revenues	27	28.115	12.717	41.936	41.511
Financial expenses	27	(73.227)	(5.846)	(175.739)	(98.071)
		<u>(45.112)</u>	<u>6.871</u>	<u>(133.803)</u>	<u>(56.560)</u>
OPERATING INCOME (LOSS) AND BEFORE INCOME TAX AND SOCIAL CONTRIBUTION		<u>22.184</u>	<u>(22.993)</u>	<u>74.942</u>	<u>16.011</u>
INCOME TAX AND SOCIAL CONTRIBUTION					
Current	29	-	-	(46.546)	(27.287)
Deferred	29	-	-	12.826	(4.349)
NET INCOME (LOSS) FOR THE YEAR		<u>22.184</u>	<u>(22.993)</u>	<u>41.222</u>	<u>(15.625)</u>
ATTRIBUTED TO					
Controlling shareholders				22.184	(22.993)
Non-controlling shareholders				<u>19.038</u>	<u>7.368</u>
				<u>41.222</u>	<u>(15.625)</u>
EARNINGS (LOSSES) PER SHARE					
Basic (cents per share - in R\$)	28	<u>0,0431</u>	<u>(0,0484)</u>		
Diluted (cents per share - in R\$)	28	<u>0,0429</u>	<u>(0,0484)</u>		

See the accompanying notes to the financial statements

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

STATEMENTS OF COMPREHENSIVE INCOME

FOR THE YEARS ENDED MARCH 31, 2023 AND MARCH 31, 2022

(In thousands of reais – R\$)

	<u>Parent Company</u>		<u>Consolidated</u>	
	<u>01/01/2023– 03/31/2023</u>	<u>01/01/2022– 3/31/2022</u>	<u>01/01/2023– 3/31/2023</u>	<u>01/01/2022– 3/31/2022</u>
NET INCOME (LOSS) FOR THE YEAR	22.184	(22.993)	41.222	(15.625)
Items that may be reclassified in the statement of income:				
Exchange-rate change in the translation of foreign operations	759	(4.788)	759	(4.788)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	<u>22.943</u>	<u>(27.781)</u>	<u>41.981</u>	<u>(20.413)</u>
ATTRIBUTABLE TO				
Controlling shareholders	-	-	22.943	(27.781)
Non-controlling shareholders	-	-	19.038	7.368
	<u>-</u>	<u>-</u>	<u>41.981</u>	<u>(20.413)</u>

See the accompanying notes to the financial statements

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (PARENT COMPANY AND CONSOLIDATED)
FOR THE YEARS ENDED MARCH 31, 2023 AND MARCH 31, 2022
(In thousands of reais – R\$)

	Note	Capital			Treasury shares	Capital reserve	Equity valuation adjustment	Transaction among partners	Accumulated losses	Attributable to controlling shareholders	Non-controlling interest	Total shareholders' equity
		Capital	To be paid-up	with public offering of shares								
BALANCES AT DECEMBER 31, 2021		2.207.134	-	(104.466)	(20.621)	588.005	14.955	(496.246)	(334.752)	1.854.009	450.934	2.304.943
Net loss for the year		-	-	-	-	-	-	-	(22.993)	(22.993)	7.368	(15.625)
Dividends paid to non-controlling shareholders		-	-	-	-	-	-	-	-	-	(2.569)	(2.569)
Paid-up capital		-	-	-	-	-	-	-	-	-	65.277	65.277
Exchange-rate change in the translation of foreign operations		-	-	-	-	-	(4.788)	-	-	(4.788)	-	(4.788)
Share-based payment		-	-	-	-	4.261	-	-	-	4.261	-	4.261
Transactions among partners		-	-	-	-	-	-	(4.041)	-	(4.041)	3.761	(280)
BALANCES AT MARCH 31, 2022		2.207.134	-	(104.466)	(20.621)	592.266	10.167	(500.287)	(357.745)	1.826.448	524.771	2.351.219
BALANCES AT DECEMBER 31, 2022		2.249.716	-	(104.466)	(79.396)	805.276	13.361	(478.214)	(288.492)	2.117.785	514.671	2.632.456
Net income for the year		-	-	-	-	-	-	-	22.184	22.184	19.038	41.222
Dividends paid to non-controlling shareholders		-	-	-	-	-	-	-	-	-	(169)	(169)
Paid-up capital	24. e)	-	-	-	-	-	-	-	-	-	3.126	3.126
Treasury shares acquired	24. b)	-	-	-	(14.057)	-	-	-	-	(14.057)	-	(14.057)
Exchange-rate change in the translation of foreign operations		-	-	-	-	-	759	-	-	759	-	759
Share-based payment	24. c)	-	-	-	-	7.369	-	-	-	7.369	-	7.369
Transactions among partners	24. d)	-	-	-	-	-	-	(112.001)	-	(112.001)	(9.222)	(121.223)
BALANCES AT MARCH 31, 2023		2.249.716	-	(104.466)	(93.453)	812.645	14.120	(590.215)	(266.308)	2.022.039	527.444	2.549.483
See the accompanying notes to the financial statements		-	-	-	-	-	-	-	-	-	-	-

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED MARCH 31, 2023 AND MARCH 31, 2022
(In thousands of reais – R\$)

Note	Parent Company		Consolidated	
	01/01/2023–0 3/31/2023	01/01/2022–0 3/31/2022	01/01/2023–0 3/31/2023	01/01/2022–0 3/31/2022
CASH FLOW FROM OPERATING ACTIVITIES				
Net income (loss) for the year	22.184	(22.993)	41.222	(15.625)
Adjustments to reconcile net income (loss) for the year with net cash generated by operating activities:				
Depreciation and amortization	26	10.474	5.713	60.250
(Reversal) provision for expected credit loss and disallowances	25	169	438	18.647
Equity in net income of subsidiaries	11	(73.789)	14.074	(97)
Yield from securities		(3.389)	(853)	(10.088)
Interest on loans, financing, debentures and drawee risk	27	47.306	2.543	123.279
Interest from lease	27	290	501	9.535
Interest referring to related parties and acquisitions		7.169	506	9.729
Adjustment to present value	27	1.709	-	3.564
Adjustment to fair value	27	712	-	5.839
Provision for Phantom Shares and Stock Options	26	7.920	5.287	7.920
Exchange-rate change		(2.182)	-	(4.539)
Mark-to-market - Swap	27	(3.270)	-	(718)
Deferred income tax and social contribution	29	-	-	(12.826)
Write-off of property, plant and equipment and intangible assets	26	-	-	308
Provision (reversal of provision) for tax, labor and civil risks	26	(56)	106	(1.140)
		<u>15.247</u>	<u>5.322</u>	<u>250.885</u>
				<u>105.513</u>
Changes in operating assets and liabilities:				
Trade accounts receivable	33	(3.026)	(3.363)	(290.173)
Inventories		409	(4.994)	12.493
Recoverable taxes		(1.968)	(519)	(38.918)
Judicial deposits		13	-	(1.021)
Other assets		(2.710)	(5.984)	(8.214)
Suppliers		(16.057)	(1.686)	(73.939)
Tax liabilities	33	1.163	17	58.733
Social charges	33	(12.673)	(7.795)	(6.040)
Other liabilities		(178)	(3.005)	(15.558)
		<u>(35.027)</u>	<u>(27.329)</u>	<u>(362.637)</u>
				<u>(208.472)</u>
Interest paid on loans, financing, debentures, leases and acquisitions	14 17 18 21	(24.339)	(3.369)	(95.678)
Income tax and social contribution paid	33	-	-	(39.316)
Net cash invested in operating activities		<u>(44.119)</u>	<u>(25.376)</u>	<u>(246.746)</u>
				<u>(171.994)</u>
CASH FLOW FROM INVESTMENT ACTIVITIES				
Payment upon acquisitions of business, net of cash acquired	33	-	-	(8.250)
Ownership interest purchase		-	(1.020)	-
Acquisition of property, plant and equipment and intangible assets	33	(11.178)	(8.380)	(44.267)
Advance payment for construction of undertaking		-	-	(4.000)
Trading securities		475.505	67.020	478.919
Advance for future capital increase	33	(88.592)	(33.428)	-
Related parties		(290.373)	(9.567)	(2.932)
Net cash generated in investment activities		<u>85.362</u>	<u>14.625</u>	<u>423.470</u>
				<u>303.757</u>
CASH FLOW FROM FINANCING ACTIVITIES				
Suppliers - Credit granting		-	-	(190.767)
Funding of loans and financing	17	-	-	391.709
Settlement of swap		(8.868)	-	(11.664)
Amortization of loans and financing	17	-	(35.000)	(47.366)
Payment of acquisitions	33	-	(376)	(133.606)
Share redemption payment		-	-	(9.431)
Payment of intangible assets	22	(4.723)	-	(4.723)
Dividends paid		-	-	(659)
Debits with related parties		(39.404)	353	767
Payment of leased assets	14.2	(1.463)	(1.211)	(13.350)
Capital increase	24 e)	-	-	3.126
Acquisition of treasury shares	24 b)	(14.057)	-	(14.057)
Advance for future capital increase	33	-	-	-
		<u>(68.515)</u>	<u>(36.234)</u>	<u>(30.021)</u>
Net cash generated by financing activities				<u>118.263</u>
Effect of changes in exchange rate on balance of cash and cash equivalents in foreign currencies		-	-	(154)
		<u>(27.272)</u>	<u>(46.985)</u>	<u>146.549</u>
				<u>13.077</u>
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS				
Cash and cash equivalents at the beginning of the year	5	79.931	398.436	263.208
Cash and cash equivalents at the end of the year	5	52.659	351.451	409.757
		<u>(27.272)</u>	<u>(46.985)</u>	<u>146.549</u>
				<u>13.077</u>

See the accompanying notes to the financial statements

STATEMENTS OF ADDED VALUE
FOR THE YEARS ENDED MARCH 31, 2023 AND 2022
(In thousands of reais – R\$)

	Note	Parent Company		Consolidated	
		01/01/2023– 03/31/2023	01/01/2022–0 3/31/2022	01/01/2023–0 3/31/2023	01/01/2022– 03/31/2022
Revenues		58.715	47.890	1.385.169	865.999
Rendering of services	25	58.807	48.113	1.395.595	879.387
Revenues from construction of own assets and leasehold improvements		77	215	8.221	5.076
Provision for expected credit losses and disallowances	25	(169)	(438)	(18.647)	(18.464)
Inputs acquired from third parties		(38.362)	(39.209)	(841.467)	(582.743)
Cost of services rendered		(32.880)	(27.609)	(737.635)	(507.092)
Materials, energy, outsourced services		(5.748)	(11.626)	(104.054)	(76.091)
Other		266	26	222	440
Gross added value		20.353	8.681	543.702	283.256
Retentions		(10.474)	(5.713)	(60.250)	(34.980)
Depreciation and amortization	26	(10.474)	(5.713)	(60.250)	(34.980)
Net added value		9.879	2.968	483.452	248.276
Added value received as transfer		101.904	(1.357)	42.033	41.511
Equity in net income of subsidiaries	11	73.789	(14.074)	97	-
Financial revenues	27	28.115	12.717	41.936	41.511
Total added value		111.783	1.611	525.485	289.787
Distribution of added value		111.783	1.611	525.485	289.787
Personnel and charges		11.631	15.491	159.578	96.149
Direct remuneration		10.849	14.417	124.500	72.339
Benefits		566	897	27.057	17.769
FGTS (severance indemnity fund)		216	177	8.021	6.041
Taxes, rates and contributions		4.586	4.189	145.842	105.334
Federal		2.887	2.640	111.107	82.580
Municipal		1.699	1.549	34.735	22.754
Third-party capital remuneration		73.382	4.924	178.843	103.929
Financial expenses	27	73.227	5.846	175.739	98.071
Expenses with occupation		155	(922)	3.104	5.858
Remuneration of own capital		22.184	(22.993)	41.222	(15.625)
Dividends		-	-	-	-
Retained earnings (losses)		22.184	(22.993)	22.184	(22.993)
Non-controlling interest in retained earnings		-	-	19.038	7.368
		-	-	-	-

See the accompanying notes to the financial statements

ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

NOTES TO THE INTERIM FINANCIAL STATEMENTS

FOR THE PERIOD ENDED MARCH 31, 2023

(In thousands of reais - R\$, unless otherwise indicated)

1. OPERATIONS

Oncoclínicas do Brasil Serviços Médicos S.A. (“Company”, “Parent Company” or “Oncoclínicas”), headquartered in São Paulo-SP, established in 2010, is a publicly-held company since August 2021, listed on the Novo Mercado of B3 S.A., whose shares are traded under ticker symbol ONCO3. The Company and its subsidiaries (collectively “Group” or “Oncoclínicas Group”) provide healthcare services, mainly focused on Oncology.

Since its establishment, the Company, in addition to providing treatment to oncology patients, has been dedicated to studying and identifying the most appropriate therapy opportunities for patients and growth trends in the industry. In essence, the patient is the center of everything, reason why Oncoclínicas Group is always looking for the most advanced treatments and the highest quality and safety levels.

Oncoclínicas’ mission is to “beat the cancer”.

The Company's controlling shareholder is The Goldman Sachs Group, Inc. (“Goldman Sachs”), in addition to minority shareholders, including Mr. Bruno Lemos Ferrari. The shareholding structure is presented in Note 24.

The Oncoclínicas Group is an oncology network in Brazil composed of 133 operating units in 2023, operating in 35 cities in the specialized areas of chemotherapy (78 units), diagnostic medicine (32 units), radiotherapy (13 units), hospitals (9 units) and oral drugs (1 unit).

Transactions in progress

- Cancer Center São Paulo

On September 1, 2022, Oncoclínicas signed a binding memorandum of understanding with Unimed Nacional (“UN”) for the joint investment in a new hospital complex and integrated cancer treatment center, called Cancer Center São Paulo, which will comprise an area totaling approximately 40,000 m², close to important city roads and with privileged visibility and accessibility, with an estimated completion time of 36 months. The planned investment for this project is approximately R\$ 300,000.

Oncoclínicas will hold a 75% interest in the Cancer Center São Paulo, while Unimed Nacional will hold a 25% interest, acting as one of the investors and commercial partners in this venture. Unimed Nacional's investment in the cancer center will be associated with the integration of the type of care for its cancer patients.

The completion of this transaction is subject to the signature of the definitive documents and the verification of certain usual precedent conditions provided for in the Transaction documents, among them the approval of the transaction by the Administrative Council for Economic Defense (CADE).

- Unimed Nacional Partnership Expansion

On October 7, 2022, the Company's Board of Directors approved the signing of a binding memorandum of understanding between Unimed Nacional and Oncoclínicas. The purpose of the partnership is to create a new company focused on offering full oncological care services to cooperatives that are members of the Unimed System, which choose to join the partnership throughout Brazil.

The subsidiary will have a shareholding structure of at least 50.01% interest for Oncoclínicas and up to 49.99% for Unimed Nacional, depending on the allocation of the share capital required for future partnerships or long-term commercial agreements that may be signed between the company and Unimed Nacional, and each Unimed, belonging to the Unimed System, that chooses to associate with it.

The completion of the transaction is subject to the signing of the definitive documents and the verification of certain precedent conditions, including, without limitation, the approval of the Administrative Council for Economic Defense (CADE).

- Porto Seguro's Investment Agreement

On December 17, 2022, the Company signed an investment agreement with Porto Seguro Serviços e Comércio S.A. ("Porto Seguro"), creating a partnership between the Company and Porto Seguro for the creation of a subsidiary for the provision of oncology medical services, whose share capital must be wholly owned by both, in the proportion of 60% for Oncoclínicas and 40% for Porto Seguro. For the partnership described, an investment of up to R\$ 160,000 will be made.

The completion of this transaction is subject to the fulfillment of certain usual precedent conditions, among them the approval of the transaction by the Administrative Council for Economic Defense (CADE).

- Cancer Center in Goiânia

On January 31, 2023, Oncoclínicas signed definitive documents for the development of a new hospital complex of excellence and an integrated cancer treatment center - the Cancer Center - in the city of Goiânia, which will comprise a total area of approximately 34,000 m², close to important roads in the city and with privileged visibility and accessibility, with completion estimated for 36 months. The planned investment for this project is approximately R\$ 145,000.

The effectiveness of this transaction is subject to the fulfillment of certain usual precedent conditions, among them the presentation by the lessor of the updated registration of the property object of the Cancer Center.

- Acquisition of Instituto Paulista de Oncologia e Cuidados Paliativos Ltda.

On February 3, 2023, Baikol Oncologia e Participações S.A. ("Baikal"), a subsidiary of the Company, signed a purchase and sale agreement for 100% of the shares of Instituto Paulista De Oncologia E Cuidados Paliativos Ltda ("Innomed") for the amount of R\$ 10,000.

The closing of the above transaction is subject to the signature of the definitive documents and the verification of certain usual precedent conditions provided for in the transaction documents, among them, obtaining the consent of financial institutions to carry out the transaction.

2. DESCRIPTION OF SIGNIFICANT ACCOUNTING POLICIES

Statement of conformity

The individual and consolidated interim financial information has been prepared in accordance with technical pronouncement CPC 21 (R1) - “Interim Financial Reporting” and the consolidated interim financial information in accordance with the standards of CPC 21 (R1) and IAS 34 – Interim Financial Reporting issued by the International Accounting Standards Board (IASB) and presented in line with the standards issued by the Brazilian Securities and Exchange Commission (“CVM”), applicable to the preparation of Interim Financial Information (ITR).

All relevant transactions of other relevant interim financial information, and only this information, are being highlighted and correspond to those used in the Company's management.

2.1. Preparation basis

The information regarding the bases for the preparation and presentation of interim financial information, the description of significant accounting policies and the use of estimates and judgment have not changed in relation to those disclosed in Notes to the annual financial statements for the year ended December 31, 2022 (hereinafter referred to as “Financial statements as of December 31, 2022”); therefore, the interim information should be read together with the Financial Statements for the year ended December 31, 2022.

The reading of the financial information must consider these aspects.

2.2. Investments in subsidiaries and consolidation

The interim financial information includes the operations of the Company and its investees and subsidiaries, whose percentage interest (direct and indirect) on the reporting date are provided below:

Investee (%)	03/31/2023			12/31/2022		
	Direct	Indirect	Total	Direct	Indirect	Total
1) Oncobio Serviços de Saúde S.A.	100.00	-	100.00	100.00	-	100.00
2) Oncocentro Imagem Serviços Médicos Ltda.	91.78	8.22	100.00	91.78	8.22	100.00
3) Cruz Participações Ltda (Talassa Participações S.A.)	50.01	-	50.01	50.01	-	50.01
4) Talia Participações Ltda.	99.90	0.10	100.00	99.90	0.10	100.00
5) Oncohematologia Participações Ltda.	99.61	0.39	100.00	99.61	0.39	100.00
6) Oncologia Participações Ltda.	92.15	7.85	100.00	92.14	7.86	100.00
7) Pontus Participações Ltda.	50.01	-	50.01	50.01	-	50.01
8) Oncopar Sul Empreendimentos e Participações Ltda.	94.82	5.18	100.00	94.81	5.19	100.00
9) Idengene Medicina Diagnóstica S.A.	94.09	5.91	100.00	92.76	7.24	100.00
10) Centro Paulista de Oncologia S.A.	99.72	-	99.72	99.50	-	99.50
11) Radioterapia Oncoclínicas Ribeirão Preto Ltda.	99.08	0.92	100.00	99.00	1.00	100.00
12) Radioterapia Oncoclínicas São Paulo Ltda.	98.90	1.10	100.00	98.09	1.10	100.00
13) Oncoclínicas Participações SP Ltda.	45.88	54.12	100.00	45.79	54.21	100.00
14) Central de Gestão e Saúde Ltda.	99.90	0.10	100.00	99.90	0.10	100.00
15) Radioterapia Oncoclínicas Salvador Ltda.	68.06	31.94	100.00	99.00	1.00	100.00
16) Oncoclínicas Salvador S.A.	100.00	-	100.00	100.00	-	100.00
17) Centro Mineiro de Infusão S.A.	69.13	30.87	100.00	69.15	30.85	100.00
18) Navarra RJ (Leste Fluminense S.A.)	51.00	-	51.00	51.00	-	51.00
19) Oncoclínicas Participações ES RJ Ltda.	99.99	0.01	100.00	99.99	0.01	100.00
20) CTC Oncologia S.A.	50.00	-	50.00	50.00	-	50.00
21) Centro de Excelência de RT do Rio de Janeiro S.A.	50.00	-	50.00	50.00	-	50.00
22) Oncoclínicas Centro de Tratamento Oncológico S.A.	38.24	61.76	100.00	31.65	68.35	100.00
23) Unity Participações S.A. (iv)	100.00	-	100.00	100.00	-	100.00
24) Hematológica - Clínica de Hematologia S.A.	100.00	-	100.00	100.00	-	100.00
25) Radiogroup Participações S.A.	-	80.00	80.00	-	80.00	80.00
26) Radiocare Serviços Médicos Especializadas Ltda.	-	100.00	100.00	-	100.00	100.00
27) Centro de Tratamento em Radioterapia Ltda.	-	100.00	100.00	-	100.00	100.00
28) Centro de Quimioterapia Antineoplásica e Imunoterapia S.A.	-	100.00	100.00	-	100.00	100.00
29) COT - Centro Oncológico do Triângulo S.A.	-	65.00	65.00	-	65.00	65.00
30) COT - Radioterapia Ltda.	-	99.99	100.00	-	100.00	100.00

Investee (%)	03/31/2023			12/31/2022		
	Direct	Indirect	Total	Direct	Indirect	Total
31) Oncocentro Uberlândia S.A.	-	100.00	100.00	-	100.00	100.00
32) Oncoclínicas Participações Minas Gerais S.A.	-	87.75	87.75	-	87.75	87.75
33) Núcleo de Hematologia e Transplante Óssea de MG Ltda.	-	100.00	100.00	-	100.00	100.00
34) Instituto de Hematologia e Oncologia de Curitiba S.A. – Clínica Médica	-	72.00	72.00	-	72.00	72.00
35) Centro de Quimioterapia Oncoclínicas S.A.	-	100.00	100.00	-	100.00	100.00
36) Oncoclínicas Canoas Clínica de Oncologia Ltda.	-	100.00	100.00	-	100.00	100.00
37) Pro Onco Centro de Tratamento Oncológico S.A.	-	75.00	75.00	-	75.00	75.00
38) CPO - Centro Paraibano de Oncologia S.A.	14.00	86.00	100.00	14.00	86.00	100.00
39) Núcleo de Oncologia da Bahia S.A.	-	80.16	80.16	-	82.32	82.32
40) Núcleo de Oncologia da Bahia Centro de Prevenção Ltda.	-	99.95	99.95	-	99.95	99.95
41) Núcleo de Oncologia de Sergipe S.A.	-	99.99	99.99	99.99	0.001	100.00
42) Multihemo Serviços Médicos S.A.	-	99.99	100.00	99.99	0.001	100.00
43) Radioterapia Oncoclínicas Recife S.A.	7.00	93.00	100.00	7.00	93.00	100.00
44) Onco Clínica Recife Ltda.	-	99.99	99.99	-	99.99	99.99
45) Radioterapia Botafogo S.A.	-	100.00	100.00	-	100.00	100.00
46) Centro de Excelência Oncológica S.A.	-	50.00	50.00	-	50.00	50.00
47) CECON - Centro Capixaba de Oncologia S.A.	-	81.50	81.50	-	81.50	81.50
48) Helmond Oncologia S.A.	-	50.00	50.00	-	50.00	50.00
49) Instituto de Oncologia de Ribeirão Preto S.A.	4.50	81.50	86.00	4.50	81.50	86.00
50) Onco Vida Instituto Especializado de Oncologia Clínica S.A.	-	100.00	100.00	-	84.40	84.40
51) Aliança Instituto de Oncologia S.A.	-	100.00	100.00	-	80.00	80.00
52) Oncoclínicas Rio de Janeiro S.A.	-	100.00	100.00	-	100.00	100.00
53) Boston Lighthouse Innovations Inc.	-	90.28	90.28	-	90.28	90.28
54) Yukon Participações S.A.	-	50.01	50.01	-	50.01	50.01
55) Baikal Participações S.A.	-	50.01	50.01	-	50.01	50.01
56) Angara Participações S.A.	-	50.01	50.01	-	50.01	50.01
57) Locus Anat. Patol. e Citologia Ltda.	-	100.00	100.00	-	100.00	100.00
58) Hospital de Oncologia do Méier S.A.	-	100.00	100.00	-	100.00	100.00
59) Ira Instituto Roberto Alvarenga Ltda.	-	95.00	95.00	-	95.00	95.00
60) Instituto Materno Infantil de Minas Gerais S.A.	-	85.00	85.00	-	85.00	85.00
61) Investment fund in credit rights – FIDC	-	-	-	-	100.00	100.00
62) Centro Brasileiro de Radioterapia Oncologia e Mastologia Cebrom Ltda.	31.65	68.35	100.00	31.65	68.35	100.00
63) CTR Centro de Tratamento Radioterápico Ltda.	-	87.56	87.56	-	87.56	87.56
64) Complexo Hospitalar Uberlândia S.A.	-	100.00	100.00	-	100.00	100.00
65) UMC Imagem Ltda.	-	100.00	100.00	-	100.00	100.00
66) Instituto do Coração do Triângulo Mineiro Ltda.	-	100.00	100.00	-	100.00	100.00
67) CAM – Clínica de Assistência à Mulher Ltda.	-	100.00	100.00	-	100.00	100.00
68) CLION – Clínica de Oncologia Ltda.	-	100.00	100.00	-	100.00	100.00
69) GMN – Grupo de Medicina Nuclear Ltda.	-	100.00	100.00	-	100.00	100.00
70) JPC – Patologia e Análises Clínicas Ltda.	-	100.00	100.00	-	100.00	100.00
71) OSTEO – Centro de Diagnóstico da Osteoporose Ltda.	-	100.00	100.00	-	100.00	100.00
72) CTR – Centro de Tratamento Radioterápico de Anápolis Ltda.	-	86.69	86.69	-	86.79	86.79
73) Microimagem Laboratório de Anatomia Patológica e Citopatologia Ltda.	-	100.00	100.00	-	100.00	100.00
74) CEMISE - Centro De Medicina Integrada De Sergipe Eireli	-	100.00	100.00	-	100.00	100.00
75) CEMISE - Ressonância Magnética e Tomografia Computadorizada Ltda.	-	100.00	100.00	-	100.00	100.00
76) ELO Medicina Diagnóstico Ltda.	-	100.00	100.00	-	100.00	100.00
77) Brasil Memorial Holding S.A.	-	100.00	100.00	-	100.00	100.00
78) Itaipara Memorial Hospital Dia Ltda.	-	97.50	97.50	-	97.50	95.50
79) Salvador Memorial Empreendimentos Médicos Ltda.	-	94.00	94.00	-	94.00	94.00
80) Clínica de Mastologia da Bahia S.A.	-	52.80	52.80	-	52.80	52.80
81) Andrômeda Participações Ltda.	-	100.00	100.00	-	100.00	100.00
82) JHSL Consultoria S.A.	55.46	-	55.46	55.46	-	55.46
83) Cardiomobile Cardiologia Móvel Ltda. (i)	-	100.00	100.00	-	-	-
84) Unidade de Oncologia Clínica e Pediátrica Ltda. (i)	-	100.00	100.00	-	-	-

(i) Refers to new acquisitions, as mentioned in Note 4.

(ii) Refers to acquisitions of remaining interests, as mentioned in Note 11.

2.3. Comparability

The statement of income for the period ended March 31, 2022 does not include the full results of CTR Anápolis, which started to be consolidated as of February 8, 2022, Elo, which started to be consolidated as of February 15, 2022, Cemise Integrada and Cemise RM, which started being consolidated as of March 4, 2022.

Statement of income for the period ended March 31, 2023 does not include the full results of the investees: Cardiomobile and UOCP, which began to be consolidated as of February 1, 2023.

The reading of the financial information must consider these aspects.

3. NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS OF STANDARDS

In the three-month period ended March 31, 2023, there were no new CPC/IFRS standards or ICPC/International Financial Reporting Interpretations Committee (“IFRIC”) interpretations issued with significant effects on the Group.

Standards issued but not yet effective

There were no new standards issued but not yet effective other than those already disclosed in the annual financial statements.

4. BUSINESS COMBINATION

The fair value of assets acquired and liabilities assumed in a business combination during the three-month period ended March 31, 2023, as well as the fair value of identifiable assets and goodwill earned were recorded on a provisional basis, with the final determination of goodwill occurring within a period of twelve months. They are stated as follows:

In 2023	São Paulo	Minas Gerais	
Location	Unidade de Oncologia Clínica e Pediátrica Ltda.	Cardiomobile Cardiologia Móvel Ltda.	
Company			
Acquisition date	02/01/2023	02/02/2023	
Acquired ownership interest (% voting)	100%	100%	Total
Payment on acquisition date	6,500	2,400	8,900
Accounts payable for acquisition	-	500	500
Total consideration	6,500	2,900	9,400
Acquired assets	1,229	1,963	3,192
Cash and cash equivalents	2	648	650
Accounts receivable	1,179	499	1,678
Recoverable taxes	36	29	65
Advances	1	-	1
Property, plant and equipment	11	787	798
Liabilities assumed	(682)	(2,246)	(2,928)
Suppliers and accounts payable	(248)	(179)	(427)
Social charges	(46)	(55)	(101)
Tax liabilities	(24)	(45)	(69)
Loans and financing	-	(1,839)	(1,839)
Advance for future capital increase	(329)	-	(329)
Other liabilities assumed	(34)	(129)	(163)
Total net assets acquired	547	(283)	264
Non-controlling shareholders	-	-	-
Excess price paid on the acquisition	5,953	3,183	9,136
Contribution to line item "Revenue" since the acquisition date	529	1,049	1,578
Contribution to line item income (loss) before taxes since the acquisition date	235	32	676
Acquiree's revenue since the beginning of the current year	804	1,636	2,440
Acquiree's income before taxes since the beginning of the year	187	146	333

Acquisitions made in 2023

(a) Unidade de Oncologia Clínica e Pediátrica Ltda. (UOCP)

Refers to the purchase and sale agreement, where the control and effective acquisition of UOCP was performed by Centro Paulista de Oncologia S.A. (CPO-SP) on February 1, 2023. UOCP is located in São Paulo and engaged in the provision of professional medical services, especially in the areas of clinical and pediatric oncology, advisory and consultancy in the medical field; and holding ownership interest in other companies as a quotaholder or shareholder.

Negotiated price

Pursuant to the purchase and sale agreement, 100% of the shares comprising the capital of UOCP was acquired by CPO SP for R\$ 6,500.

Goodwill on business combination

For the purposes of this business combination, the amount of R\$ 5,953 was recognized as goodwill based on expected future earnings by buyer CPO SP due to expected business combination synergies.

(b) Cardiomobile Cardiologia Móvel Ltda. (“CARDIOMOBILE”)

Refers to the purchase and sale agreement, where the control and effective acquisition of Cardiomobile Cardiologia Móvel Ltda was carried out by UMC Imagem Ltda on February 2, 2023. Located in Minas Gerais, Cardiomobile is engaged in providing medical services in nuclear medicine, hemodynamics, telemedicine and diagnostic imaging.

Negotiated price

Pursuant to the purchase and sale agreement, 100% of the shares comprising the capital of CARDIOMOBILE was acquired by UMC Imagem Ltda for R\$ 2,900.

Goodwill on business combination

For the purposes of this business combination, the amount of R\$ 3,183 was recognized as goodwill based on expected future earnings by buyer UMC Imagem Ltda. due to expected business combination synergies.

Changes in acquisitions made in 2022

During the first quarter of 2023, the Company completed the Purchase Price Allocation (PPA) of acquiree Elo Medicina Diagnostica Ltda, for final recognition of goodwill.

As part of this exercise, the Company made certain changes in the opening balances and, based on an internal analysis, it understood that the amounts changed are immaterial. Accordingly, the information disclosed in the financial statements as of December 31, 2022 is not being restated.

The changes are explained below:

(a) Elo Medicina Diagnostica Ltda.

The impacts of the review of the purchase price allocation resulted in a decrease in goodwill acquired in a business combination in the amount of R\$ 535 arising from the surplus of property, plant and equipment.

The allocation of the acquisition price and the measurement of the goodwill on the acquisition of equity interest were established as follows:

	Previously disclosed	Balance at 03/31/2023
Consideration offered	2,000	2,000
Surplus of property, plant and equipment	-	535
Total assets acquired and liabilities assumed	<u>(2,755)</u>	<u>(2,220)</u>
Goodwill	<u>4,755</u>	<u>4,220</u>

During the first quarter of 2023, the Company reviewed the temporary purchase price allocation of the business combinations below, which continues to be subject to changes during the 12-month measurement period established by the applicable accounting practices. Currently, the impacts arising from this review are:

(b) Unity group

The impact of the preliminary review of the purchase price allocation resulted in an increase in the temporary goodwill acquired in a business combination in the amount of R\$ 22,653, of which R\$ 21,373 arising from adjustments to accounts receivable related to the adequacy of revenue recognition in accordance with the Group's practices and R\$ 600 referring to the adjustment in the lease balance.

	Previously disclosed	Balance at 03/31/2023
Accounts receivable	129,379	108,106
Leases	(1,596)	(2,196)
Total assets acquired and liabilities assumed	<u>8,863</u>	<u>(13,789)</u>
Goodwill	<u>816,251</u>	<u>838,903</u>

(c) JHSL Consultoria S.A.

The impact of the preliminary review of the price allocation, resulted in an increase in the temporary goodwill acquired in a business combination in the amount of R\$ 1,306, of which R\$ 509 refers to the amount initially paid before obtaining control of the acquiree.

	Previously disclosed	Balance at 03/31/2023
Consideration offered	1,300	1,300
Total assets acquired and liabilities assumed	1,218	421
Goodwill determined before business combination	<u>-</u>	<u>509</u>
Goodwill	<u>82</u>	<u>1,388</u>

(d) Clínica de Mastologia da Bahia S.A. – “Núcleo da Mama”

The impact of the preliminary review of the purchase price allocation, resulted in an increase in the temporary goodwill acquired in a business combination in the amount of R\$ 428, arising from the price adjustment provided for in the purchase and sale agreement of R\$ 54 and negative change in the net assets acquired in the amount of R\$ 374.

	Previously disclosed	Balance at 03/31/2023
Consideration offered	590	644
Total assets acquired and liabilities assumed	435	60
Goodwill	155	582

5. CASH AND CASH EQUIVALENTS

	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Cash and banks	428	698	55,434	45,649
Interest earning bank deposits	52,231	79,233	354,323	217,559
Total cash and cash equivalents	52,659	79,931	409,757	263,208

Interest earning bank deposits are mainly represented by Bank Deposit Certificates (CDBs) yielding interest corresponding to rates of up to 102.45 as of March 31, 2023 (100.16% as of December 31, 2022) of the Interbank Deposit Certificate (CDI) rate, highly liquid.

6. SECURITIES AND OTHER FINANCIAL ASSETS

	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Fixed income investments	121,998	594,116	372,907	841,738
Total	121,998	594,116	372,907	841,738
Current (i)	121,233	593,351	360,857	829,594
Non-current (ii)	765	765	12,050	12,144

(i) The short-term interest earning bank deposits refer to investments in highly liquid fixed-income securities but which, however, do not meet all criteria for classification as cash and cash equivalents.

(ii) Long-term interest earning bank deposits are substantially derived from fixed income fund shares.

The yield of these short-term investments is approximately 91.06% of the CDI for March 31, 2023 (91.63% of the CDI for December 31, 2022).

7. TRADE ACCOUNTS RECEIVABLE

	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Clients	10,634	13,811	882,641	698,389
Unbilled revenues	30,526	24,387	876,244	834,360
Total trade accounts receivable and unbilled revenues	41,160	38,198	1,758,885	1,532,749
Provision for expected credit losses (ECL)	(3,944)	(3,865)	(69,282)	(123,245)
Provision for disallowance	(1,098)	(1,071)	(58,158)	(29,890)
	36,118	33,262	1,631,445	1,379,614

Trade accounts receivable are denominated in Brazilian reais and refer mainly to services provided to agreements, whose receipts occur, on average, in 113 days, as of March 31, 2023 (98 days as of December 31, 2022).

To determine the collection period, the Group considers the balance of trade accounts receivable in relation to the average revenue for the last three months preceding the reporting date.

The increase in the balance is mainly represented by the renegotiation of the payment term for large operators, with low risk rating and with balance partially settled in April.

The breakdown of accounts receivable per maturity date is stated as follows:

	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Falling due	35,712	31,405	1,177,109	1,206,496
Overdue up to 30 days	225	1,191	170,146	131,597
Overdue up to 60 days	135	274	210,414	86,155
Overdue up to 90 days	345	682	74,364	59,678
Overdue, 91–180 days	312	762	71,803	32,201
Overdue >180 days	4,431	3,884	55,050	16,622
	<u>41,160</u>	<u>38,198</u>	<u>1,758,885</u>	<u>1,532,749</u>

Changes in the estimated allowance for doubtful accounts and disallowances are as follows:

	Parent Company	Consolidated
Balance at December 31, 2021	(5,541)	(45,020)
Reversal	1,784	15,844
Recognition	(1,410)	(31,491)
New acquisitions	-	-
Balance at March 31, 2022	<u>(5,167)</u>	<u>(60,667)</u>
Balance at December 31, 2022	(4,936)	(153,135)
Reversal	3,298	107,704
Recognition	(3,404)	(82,009)
Balance at March 31, 2023	<u>(5,042)</u>	<u>(127,440)</u>

The maximum exposure to credit risk on the balance sheet date is the book value of each of the types of accounts receivable mentioned above. The Oncoclínicas Group does not maintain any note as accounts receivable guarantee.

8. INVENTORIES

	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Medicines	7,182	7,705	108,432	122,002
Material and Personal Protective Equipment (PPE)	9,469	9,355	43,012	41,935
Total	<u>16,651</u>	<u>17,060</u>	<u>151,444</u>	<u>163,937</u>

Inventories refer mainly to medicines used in chemotherapeutic procedures. There is no provision for inventory losses and guarantees, considering an average turnover period of approximately 37 days as of March 31, 2023 (40 days as of December 31, 2022). Additionally, there are no guarantees provided and/or restrictions on the full use of inventories.

9. RECOVERABLE TAXES

Recoverable taxes are broken down as follows:

	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
IRPJ/CSLL	28,301	12,171	84,378	38,908
Withholding IRRF/CSLL	488	15,933	1,238	31,412
PIS/COFINS	3,996	2,714	61,755	49,278
ISSQN	-	-	-	410
Payroll taxes	18,245	18,245	16,940	16,940
Other taxes	3,900	3,899	3,148	5,655
	<u>54,930</u>	<u>52,962</u>	<u>167,455</u>	<u>142,602</u>

10. OTHER ASSETS

	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Advances to suppliers	8,165	10,146	20,647	23,408
PERT in consolidation – see Note 20	-	-	1,064	1,064
Disposal of equity interests (a)	19,902	19,615	21,763	21,738
Indemnity assets (b)	-	-	35,481	35,481
Machinery lease	6,096	5,232	3,267	2,116
Sundry advances (c)	10	-	23,986	24,487
Prepaid expenses	6,546	4,662	13,774	6,830
Other	6,161	4,515	15,615	12,104
	<u>46,880</u>	<u>44,170</u>	<u>135,597</u>	<u>127,228</u>
Current	24,276	21,602	56,286	47,874
Non-current	22,604	22,568	79,311	79,354

- a) Refers to transactions involving the sale of equity interest formalized between the Company, its subsidiaries and third parties. Balances are restated according to CDI + IPCA and mature up to 2030.
- b) Includes amounts resulting from indemnifiable events by former controlling shareholders of entities acquired by the Group.
- c) Includes the amount of R\$ 13,500, prepaid for the start of works according to the agreement signed in May 2021, under the Built To Suit modality, between Hymalaia Empreendimentos Imobiliários S.A. (Lessor) and Oncoclínicas – Centro Tratamento Oncológico S.A. (CTO) (Lessee). The objective of this agreement is the development of a mixed use real estate project, planned with the integration of spaces destined to healthcare, shopping malls, residential buildings and others, which will be economically exploited by the Company or by whoever it indicates/contracts, ensuring vacancies destined exclusively for the hospital unit that will be built according to the model and approval of the lessee for later use and exploitation by the Company. The Lease term will start on the date of delivery of the property in conditions of use with a term of thirty (30) years.

The project is still in progress, and the recognition criteria established by IFRS 16 (CPC 06) have not yet been met.

11. INVESTMENTS IN SUBSIDIARIES AND ASSOCIATED COMPANIES

a) Breakdown

Description	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Investments	1,718,135	1,434,775	23,482	22,222
Goodwill (i)	996,165	974,465	-	-
Call options (ii)	15,884	15,884	-	-
Total	2,730,184	2,425,124	23,482	22,222

(i) Refers to the goodwill arising on business combinations carried out by the Parent Company.

(ii) Refers to stock options granted by minority shareholders to Núcleo de Oncologia da Bahia S.A., as described in Note 21.

Changes in the balances of investments are as follows:

Companies	12/31/2022	Capital increase	Equity in net income of subsidiaries	Changes in interest (ii)	Transfer (i)	Goodwill (iii)	Exchange-rate change	Other	03/31/2023
Chemotherapy	264,632	270,757	60,972	(59,121)	(553)	(22,652)	-	(265)	513,770
Radiotherapy	21,688	20	1,271	-	9	-	-	-	22,988
Precision medicine	150,616	50,184	(7,455)	-	(560)	-	743	-	193,528
Vehicle entities	905,135	19,156	22,192	(51,556)	1,012	-	16	(120)	895,835
Other	65,649	4,000	(3,191)	-	92	-	-	-	66,550
Total	1,407,720	344,117	73,789	(110,677)	-	(22,652)	759	(385)	1,692,671
Investments	1,434,775								1,718,135
Unsecured liability	(27,055)								(25,464)

Companies	12/31/2021	Capital increase	Equity in net income of subsidiaries	Changes in interest	Transfer	New acquisitions	Exchange-rate change	03/31/2022
Chemotherapy	59,311	-	(5,612)	-	(62,958)	-	-	(9,259)
Radiotherapy	14,461	-	449	-	-	-	-	14,910
Precision medicine	76,486	-	(10,278)	-	-	-	(4,776)	61,432
Vehicle entities	411,436	-	4,591	-	58,906	1,020	-	475,953
Other	28,242	-	(3,224)	-	-	-	-	25,018
Total	589,936	-	(14,074)	-	(4,052)	1,020	(4,776)	568,054
Investments	616,134							653,178
Unsecured liability	(26,199)							(85,124)

(i) Transfer

In the first quarter of 2023, the Company carried out transfers of interests in the corporate structure of companies by the Group, which had no effect on the consolidated investment.

(ii) Change in interest

On January 31, 2023, Oncoclínicas Participações São Paulo S.A. acquired the remaining interests, representing 15.60% of the capital of Onco Vida Instituto Especializado de Oncologia Clínica S.A. and representing 20% of the capital of Aliança Instituto Oncologia S.A.

The effect on the Company was as follows:

Company	%		Consideration	Acquired shareholders' equity	Goodwill
	Before	% After			
Onco Vida Instituto Especializado de Oncologia Clínica S.A.	84.40	100.00			
	%	%	41,688	1,869	39,819
Aliança Instituto de Oncologia S.A.	80.00	100.00			
	%	%	76,743	5,885	70,858
Total			118,431	7,754	110,677

(iii) Goodwill

As mentioned in Note 04, the Company revisited the assets acquired and liabilities assumed in business combinations, which led to a change in the temporary goodwill recorded for the acquiree Unity Participações in the amount of R\$ 22,652.

Equity position of direct investees							
March 31, 2023							
Company	Interest	Total assets	Total liabilities	Shareholders' equity	Income (loss) for the year	Investment value	MEP result - from direct investees
Oncoclínicas Salvador S.A.	100.00%	16,718	4,177	12,541	1,164	12,541	1,164
Oncoclínica – Centro de Tratamento Oncológico S.A. (CTO)	38.24%	956,730	501,776	454,954	16,586	173,967	6,483
Centro Mineiro de Infusões S.A.	69.13%	719,518	152,451	567,067	5,564	392,017	3,846
Oncocentro Imagem Serviços Médicos Ltda.	91.78%	145,664	47,502	98,162	3,715	90,095	3,409
Oncopar Sul Empreendimentos e Participações Ltda.	94.82%	118,008	7,962	110,046	6,712	104,341	6,363
Oncologia Participações Ltda.	92.15%	86,555	258	86,297	1,071	79,535	986
CPO – Centro Paraibano de Oncologia S.A.	14.00%	31,521	16,389	15,132	2,341	2,118	328
Oncohematologia Participações Ltda.	99.62%	35,268	795	34,473	323	34,341	77
Oncobio Serviços de Saúde S.A.	100.00%	121,881	47,462	74,419	(2,651)	74,419	(2,651)
Instituto de Oncologia de Ribeirão Preto S.A.	4.50%	14,920	7,290	7,630	374	343	17
Radioterapia Oncoclínicas São Paulo Ltda.	98.90%	14,499	11,666	2,833	497	2,802	492
Centro Excelência de RT do Rio de Janeiro S.A.	50.00%	11,406	1,555	9,851	(680)	4,926	(340)
Radioterapia Oncoclínicas Recife S.A.	7.00%	54,239	25,930	28,309	(606)	1,982	(42)
CGS Faria Lima	99.90%	3,870	473	3,397	(4)	3,394	(4)
Idengene Medicina Diagnóstica S.A.	94.10%	243,119	41,118	202,001	(7,973)	190,079	(7,455)
Oncoclínicas Participação SP Ltda.	45.79%	107,572	98,106	9,466	5,919	4,334	2,710
Oncoclínicas Participações ES RJ Ltda.	99.99%	70,205	696	69,509	5,657	69,502	5,656
Navarra RJ (Leste Fluminense S.A.)	45.43%	146,618	55,375	91,243	10,533	41,452	4,785
Cruz Participações Ltda (Talassa Participações S.A.)	34.88%	69,565	35,481	34,084	(353)	11,887	(123)
CTC Oncologia S.A.	50.00%	240,702	1,689	239,013	3,738	119,507	1,869
Hematológica - Clínica de Hematologia S.A.	100.00%	55,443	32,687	22,756	2,210	22,756	2,210
Locus Anat. Patol. e Citologia Ltda.	9.80%	9,820	4,572	5,248	(1,073)	514	(197)
Talia Participações Ltda.	99.90%	15	3	12	-	12	-
Centro Brasileiro de Radioterapia Oncologia e Mastologia Cebrom Ltda.	31.65%	151,745	56,672	95,073	1,875	30,088	593
Centro Paulista de Oncologia S.A.	99.73%	896,256	790,837	105,419	6,780	104,814	6,384
COTE – Centro Oncológico e Tratamento	100.00%	2,047	1,458	589	(333)	589	(332)
Unity Participações S.A.	100.00%	418,018	272,229	145,780	40,172	145,780	40,172
Total investment		4,741,922	2,216,609	2,525,304	101,558	1,718,135	76,400

Company	Interest	Total assets	Total liabilities	Shareholders' equity	Income (loss) for the year	Investment amount	MEP result - from direct investees
Radioterapia Oncoclínicas Salvador Ltda.	68.06%	1	3	(2)	(3)	(1)	(2)
Radioterapia Oncoclínicas Ribeirão Preto Ltda.	99.09%	8	10	(2)	-	(2)	-
Pontus Participações Ltda.	50.01%	8,388	56,879	(48,491)	(3,520)	(25,460)	(1,760)
JHSL Consultoria S.A.	68.06%	1	3	(2)	(3)	(1)	(2)
Total unsecured liability		8,651	56,895	(48,497)	(3,526)	(25,464)	(2,611)
Total direct investments		4,750,573	2,276,008	2,474,556	98,032	1,692,671	73,789

Equity interest held in direct investees							
March 31, 2022							
Company	Interest	Total assets	Total liabilities	Shareholders' equity	Income (loss) for the quarter	Investment value	MEP result - from direct investees
Centro Mineiro de Infusões S.A.	58.80%	643,782	506,926	136,856	6,262	80,544	3,682
Oncoclínicas Salvador S.A.	100.00%	13,526	4,688	8,838	(292)	8,838	(292)
Centro Paulista de Oncologia	99.50%	875,312	854,037	21,275	(11,830)	21,110	(11,771)
Oncopar	94.81	104,796	11,605	93,191	1,485	88,240	1,408
Onco Participações	92.13%	83,562	305	83,257	690	77,202	636
RT Oncoclínicas São Paulo	50.00%	11,921	1,542	10,379	503	5,190	251
RT Oncoclínicas Recife	7.00%	49,155	41,928	7,227	(427)	506	(30)
Talassa Oncologia e Participações S.A.	28.58%	55,421	22,756	32,665	(1,214)	9,335	(347)
Louro Participações Ltda.	39.74%	235,012	40,940	194,072	(927)	77,131	(368)
Onco Part. SP	45.78%	83,126	36	83,090	2,624	38,038	1,201
Oncobio	100.00%	80,356	47,453	32,903	(3,723)	32,903	(3,723)
Instituto Onc. De Ribeirão Preto	4.50%	10,211	4,749	5,462	1,089	246	49

Oncocentro Imagem	90.85%	165,614	66,169	99,445	4,992	90,049	4,535
CPO Paraíba	14.00%	24,496	10,961	9,535	1,524	1,335	213
Idengene	99.76%	154,868	93,294	61,574	(10,303)	61,427	(10,278)
Leste Fluminense	45.43%	120,106	46,384	73,722	5,500	33,511	2,499
Centro de Gestão e Saúde	99.99%	2,625	845	1,780	500	1,778	500
Onco Part. ES RJ	99.99%	54,027	29,239	24,788	(958)	24,775	(958)
JHSL Consultoria S.A.	25.77%	473	126	347	-	1,020	-
Total investment		<u>2,764,389</u>	<u>1,783,983</u>	<u>980,406</u>	<u>(4,505)</u>	<u>653,178</u>	<u>(12,793)</u>

Company	Interest	Total assets	Total liabilities	Shareholders' equity	Income (loss) for the year	Investment amount	MEP result - from direct investees
Oncohematologia Participações Ltda.	99.17%	34,479	42,060	(7,581)	886	(7,518)	878
Radioterapia Oncoclínicas Salvador Ltda.	100.00%	-	6	(6)	(1)	(6)	(1)
Radioterapia Oncoclínicas Ribeirão Preto Ltda.	99.00%	11	30	(19)	(1)	(19)	(1)
Oncoclínicas – Centro de Tratamento Oncológico S.A.	100.00%	1,196,370	1,250,620	(54,250)	3,397	(54,250)	2,297
Pontus Participações Ltda.	50.01%	9,850	55,829	(45,979)	(12,149)	(22,994)	(6,076)
Radioterapia Oncoclínicas	99.00%	<u>13,618</u>	<u>13,959</u>	<u>(341)</u>	<u>527</u>	<u>(337)</u>	<u>522</u>
Total unsecured liability		<u>1,254,328</u>	<u>1,362,504</u>	<u>(108,176)</u>	<u>(7,341)</u>	<u>(85,124)</u>	<u>(1,281)</u>
Total direct investments		<u>4,018,717</u>	<u>3,146,487</u>	<u>872,230</u>	<u>(11,846)</u>	<u>568,054</u>	<u>(14,074)</u>

12. PROPERTY, PLANT AND EQUIPMENT

Parent Company

Description	Annual depreciation rates	03/31/2023		12/31/2022	
		Cost	Accumulated depreciation	Balance	Balance
Machinery and equipment	10%	48,920	(17,211)	31,709	32,697
Facilities	10%	559	(369)	190	201
Furniture and fixtures	10%	3,599	(2,085)	1,514	1,591
Computers and peripherals	20%	11,190	(5,459)	5,731	4,890
Leasehold improvements	10%	20,261	(9,547)	10,714	11,148
Land	-	986	-	986	986
Construction in progress	-	4,768	-	4,768	4,560
Total		<u>90,281</u>	<u>(34,671)</u>	<u>55,612</u>	<u>56,073</u>

Consolidated

Description	Annual depreciation rates	03/31/2023		12/31/2022	
		Cost	Accumulated depreciation	Balance	Balance
Machinery and equipment	8%	471,158	(211,024)	260,134	223,965
Facilities	10%	11,651	(6,200)	5,451	6,434
Furniture and fixtures	10%	61,940	(35,162)	26,778	52,306
Computers and peripherals	20%	56,315	(33,359)	22,956	22,636
Leasehold improvements	10%	440,360	(134,548)	305,812	306,831
Vehicles	25%	714	(714)	-	87
Land	-	5,395	-	5,395	4,954
Construction in progress	-	92,360	-	92,360	89,571
Total		<u>1,139,893</u>	<u>(421,007)</u>	<u>718,886</u>	<u>706,783</u>

There are no assets pledged in guarantee as of March 31, 2023 and December 31, 2022. Management has not identified significant differences in the economic useful lives of the assets part of its property, plant and equipment and of its subsidiaries.

Leasehold improvements are amortized over the term of the lease agreement and the expected renewal or disposal are considered, when Management intends to exercise this right, and pursuant to the terms of the agreements. Land and constructions in progress are not depreciated or amortized.

Oncoclínicas do Brasil Serviços Médicos S.A.

Parent Company	Machinery and equipment	Facilities	Furniture and fixtures	Computers and peripherals	Leasehold improvements	Construction in progress	Advance	Land	Total
Balance at December 31, 2021	36,897	254	1,923	3,315	12,846	3,840	1,232	986	61,293
Acquisitions	19	-	47	64	63	771	-	-	964
Depreciation	(1,322)	(13)	(95)	(390)	(512)	-	-	-	(2,332)
Balance at March 31, 2022	35,594	241	1,875	2,989	12,397	4,611	1,232	986	61,293
Balance at December 31, 2022	32,697	202	1,592	4,890	11,146	4,560	-	986	56,073
Acquisitions	61	-	11	1,335	77	208	-	-	1,692
Depreciation	(1,049)	(12)	(89)	(494)	(509)	-	-	-	(2,153)
Balance at March 31, 2023	31,709	190	1,514	5,731	10,714	4,768	-	986	55,612

Consolidated	Machinery and equipment	Facilities	Furniture and fixtures	Computers and peripherals	Leasehold improvements	Vehicles	Land	Advance	Construction in progress	Total
Balance at December 31, 2021	169,823	6,162	19,602	16,967	229,481	-	2,044	1,514	32,323	477,916
New companies	48,633	163	2,863	2,171	13,004	1	2,809	-	17,285	86,929
Acquisitions	9,399	-	1,076	1,606	4,529	-	-	-	15,471	32,081
Depreciation	(7,590)	(251)	(921)	(1,561)	(6,795)	-	-	-	-	(17,118)
Write-offs	-	-	(28)	(1)	-	-	-	-	-	(29)
Transfers	-	-	-	-	13,534	-	-	-	(13,534)	-
Balance at March 31, 2022	220,265	6,074	22,592	19,182	253,753	1	4,853	1,514	51,545	579,779
Balance at December 31, 2022	223,965	6,434	52,306	22,636	306,831	87	4,955	-	89,571	706,783
New companies	684	8	24	8	74	-	-	-	-	798
Acquisitions	8,452	40	1,290	2,004	8,221	-	-	-	11,008	31,014
Depreciation	(8,963)	(251)	(1,698)	(1,738)	(6,794)	(1)	-	-	-	(19,445)
Write-offs	-	-	(25)	(235)	(4)	-	-	-	-	(264)
Transfers	35,996	(780)	(25,119)	281	(2,516)	(86)	440	-	(8,219)	-
Balance at March 31, 2023	260,134	5,451	26,778	22,956	305,812	-	5,395	-	92,360	718,886

Loan cost capitalized

For the three-month period ended March 31, 2023, the Company capitalized interest on loans attributed to qualifying assets, in the amount of R\$ 2,616. In the period of December 31, 2022, amounts of interest were not capitalized.

The Company evaluated the impairment indicators and for the three-month period ended March 31, 2023, the need to recognize a provision for asset impairment was not identified.

13. INTANGIBLE ASSETS

The intangible assets of the Company and its subsidiaries are comprised of systems and applications, exclusivity right, software development, trademarks and patents, partnership agreements and goodwill deriving from expected future earnings paid on the acquisition of investments that are justified in the estimated future cash flows, pursuant to future feasibility reports prepared by external specialists. Goodwill arising from the acquisition of investments in subsidiaries is reclassified from the investment group in the parent company's financial statements to intangible assets in the consolidated financial statements.

The amounts recorded in intangible assets are as follows:

Description	Annual rates of amortization	Parent Company			
		03/31/2023		12/31/2022	
		Cost	Accumulated amortization	Balance	Balance
Systems and applications	20%	23,324	(12,933)	10,391	9,724
Software and project development	-	59,010	-	59,010	52,136
Exclusivity right	20%	50,629	(24,367)	26,262	24,223
Goodwill	-	9,585	-	9,585	9,585
Partnership agreement (ii)	8.33%	77,303	(1,393)	75,910	76,374
Trademarks and patents	-	270	-	270	269
Intellectual property (i)	20%	89,215	(8,992)	80,223	85,120
Total		309,336	(47,685)	261,651	257,431

Description	Annual rates of amortization	Consolidated			
		03/31/2023		12/31/2022	
		Cost	Accumulated amortization	Balance	Balance
Systems and applications	20%	71,648	(43,265)	28,383	33,162
Software and project development	-	151,844	(266)	151,578	136,823
Exclusivity right	20%	192,110	(69,326)	122,784	85,087
Goodwill on investment acquisitions	-	2,599,287	-	2,599,287	2,569,448
Partnership agreement	8.3%	1,076,710	(82,256)	994,454	1,001,670
Trademarks and patents	-	779	(4)	775	819
Intellectual property	20%	91,551	(8,992)	82,559	87,455
Total		4,183,929	(204,109)	3,979,820	3,914,464

There are no rights pledged in guarantee as of March 31, 2023 and December 31, 2022. The Company's management did not identify significant differences in the economic useful life of the assets that comprise its intangible assets and those of its subsidiaries.

	Parent Company							
	Systems and applications	Software development	Oncocentro goodwill	Exclusivity right	Trademarks and patents	Intellectual property	Partnership agreement	Total
Balance at December 31, 2021	3,739	34,342	9,585	13,524	270	8,954	-	70,413
Acquisitions	2,984	3,937	-	-	-	-	-	7,416
Amortizations	(460)	-	-	(1,604)	-	495	-	(2,064)
Balance at March 31, 2022	6,263	38,279	9,585	11,920	270	9,448	-	75,765
Balance at December 31, 2022	9,724	52,136	9,585	24,223	270	85,119	76,374	257,431
Acquisitions	2,823	5,825	-	4,128	-	766	-	13,542
Amortizations	(1,181)	-	-	(2,089)	-	(2,823)	(464)	(6,557)

Transfers	(975)	1,049	-	-	-	(2,839)	-	(2,765)
Balance at March 31, 2023	<u>10,391</u>	<u>59,010</u>	<u>9,585</u>	<u>26,262</u>	<u>270</u>	<u>80,223</u>	<u>75,910</u>	<u>261,651</u>

	Consolidated							
	Systems and applications	Software development	Partnership agreements (i)	Goodwill in investment acquisitions (ii)	Exclusivity right	Trademarks and patents	Intellectual property (iii)	Total
Balance at December 31, 2021	<u>11,296</u>	<u>100,569</u>	<u>915,560</u>	<u>1,168,973</u>	<u>30,042</u>	<u>759</u>	<u>11,210</u>	<u>2,238,409</u>
New companies	1,152	11	-	-	-	-	-	1,163
Acquisitions	624	15,327	-	472,215	-	-	572	488,738
Amortizations	(1,254)	-	(5,825)	-	(2,653)	-	-	(9,732)
Exchange-rate change	-	-	-	(3,642)	-	-	-	(3,642)
Other changes	-	-	-	4,977	-	-	-	4,977
Transfers	(234)	234	-	-	-	-	-	-
Balance at March 31, 2022	<u>11,584</u>	<u>116,141</u>	<u>909,735</u>	<u>1,642,523</u>	<u>27,389</u>	<u>759</u>	<u>11,782</u>	<u>2,719,913</u>
Balance at December 31, 2022	<u>33,162</u>	<u>136,823</u>	<u>1,001,670</u>	<u>2,569,448</u>	<u>85,087</u>	<u>819</u>	<u>87,455</u>	<u>3,914,464</u>
Acquisitions	677	11,810	-	9,136	47,186	-	767	69,576
Amortizations	(2,472)	(39)	(7,216)	-	(9,489)	-	(5,664)	(24,880)
Write-offs	-	-	-	-	-	(44)	-	(44)
Exchange-rate change	-	-	-	(884)	-	-	-	(884)
Other operations (ii)	-	-	-	21,587	-	-	-	21,587
Transfers	(2,984)	2,984	-	-	-	-	-	-
Balance at March 31, 2023	<u>28,383</u>	<u>151,579</u>	<u>994,454</u>	<u>2,599,287</u>	<u>122,784</u>	<u>775</u>	<u>82,558</u>	<u>3,979,820</u>

(i) Partnership agreements

The partnership agreements entered into at the Company refer to partnerships with other medical institutions for the provision of oncology services. Oncoclínicas contributes a certain value to the partner institution, and as a consideration, the institution indicates and transfers to the Oncoclínicas units the patients who need any type of oncology-related care. Amortization is incurred over the term signed in each partnership agreement.

(ii) Goodwill on investment acquisitions

Refers to the conclusion of the allocation of the purchase price of the acquiree Elo, which corresponds to a reduction of R\$ 535, and the review of the allocation of the purchase price of the acquirees: JHSL, Núcleo da Mama and Grupo Unity, recorded an increase in goodwill of R\$ 22,122, as presented in Note 4.

For the three-month period ended March 31, 2023 and the year ended December 31, 2022, no need was identified to recognize a provision for impairment of goodwill arising from the acquisition in a business combination.

(iii) Exclusivity right

The right of non-competition registered in the companies of the Oncoclínicas Group refers to clauses evidenced in the contracts for the provision of medical services, which provide for the exclusivity right of such service providers. The average term of the contracts is 5 years.

The Company evaluated the impairment indicators and for the three-month period ended March 31, 2023, the need to recognize a provision for asset impairment was not identified.

14. RIGHT-OF-USE AND LEASE LIABILITIES

The Group leases properties for its operations, including buildings. The average lease term is ten years. The Group's obligations are guaranteed by the ownership of the leased assets.

14.1. Right-of-use assets

	Parent Company
Balance at 12/31/2021	<u>20,799</u>
Addition	1,142
Amortization	<u>(1,317)</u>
Balance at 03/31/2022	<u><u>20,624</u></u>
Balance at 12/31/2022	12,363
Addition	1,570
Amortization	<u>(1,762)</u>
Balance at 03/31/2023	<u><u>12,171</u></u>

	Consolidated		
	Real estate	Machinery and equipment	Total
Balance at 12/31/2021	<u>241,329</u>	<u>9,823</u>	<u>251,151</u>
New companies	24,842	-	24,842
Addition	1,241	-	1,241
Amortization	<u>(7,860)</u>	<u>(270)</u>	<u>(8,130)</u>
Balance at 03/31/2022	<u><u>259,552</u></u>	<u><u>9,553</u></u>	<u><u>269,104</u></u>
Balance at 12/31/2022	374,891	8,931	383,822
Addition	4,289	-	4,289
Amortization	<u>(18,476)</u>	<u>(290)</u>	<u>(18,766)</u>
Reclassification	26	-	26
Balance at 03/31/2023	<u><u>360,730</u></u>	<u><u>8,641</u></u>	<u><u>369,371</u></u>

14.2. Lease liabilities

Liabilities were measured at the present value of the remaining lease payments as discounted through the average incremental rate of 14.91% p.a. as of March 31, 2023 (14.91% p.a. for December 31, 2022).

Due to the maturity and renewal of some lease contracts, they were remeasured at the new monthly amount, which additional amounts were classified as addition.

	Parent Company	Consolidated
Balance at 12/31/2021	23,209	269,671
New companies	-	24,842
Addition	1,142	1,241
Principal payments	<u>(1,211)</u>	<u>(6,511)</u>
Payment of interest	<u>(530)</u>	<u>(4,800)</u>
Interest incurred	501	4,864
Balance at 03/31/2022	<u><u>23,111</u></u>	<u><u>289,307</u></u>

Balance at 12/31/2022	13,990	368,830
Addition	1,572	4,289
Principal payments	(1,463)	(13,350)
Interest payment	(170)	(10,911)
Interest incurred	290	9,535
Balance at 03/31/2023	<u>14,219</u>	<u>358,393</u>
Current	5,655	81,490
Non-current	8,564	276,903

As of March 31, 2023, the breakdown of balance is as follows:

	<u>Parent Company</u>	<u>Consolidated</u>
2023	4,453	62,729
2024	6,093	76,035
2025	3,802	62,724
2026	1,020	49,466
2027	274	44,944
>2028	225	364,941
Total	<u>15,865</u>	<u>660,839</u>
Embedded interest	<u>(1,646)</u>	<u>(302,446)</u>
Lease liabilities	<u>14,219</u>	<u>358,393</u>

Although the accounting methodology used by the Company is in line with the rule provided for in CPC 06(R2) /IFRS 16, it generates distortions in the information to be provided due to the mismatching between the cash flow and present value, considering the current reality of interest rates term in the Brazilian economic environment. Thus, the Company recalculated the depreciation and financial charges for the total effective period of the active agreements on March 31, 2023, based on a future cash flow that incorporates the inflationary expectation (nominal flow).

In compliance with Circular Letter/CVM/SNC/SEP/ 02/2019, the Company presents the comparative balances of lease liabilities and its respective financial expenses, right-of-use assets and its respective depreciation expenses, considering the effect of the projected future IPCA inflation in the lease contract flows, discounted at the nominal rate:

	<u>Parent Company</u>		<u>Consolidated</u>	
	<u>IFRS 16</u>	<u>Projected inflation</u>	<u>IFRS 16</u>	<u>Projected inflation</u>
Right-of-use assets, net	12,171	16,341	369,371	438,918
Lease liabilities	14,219	15,831	358,393	476,013
Depreciation expenses	(1,762)	(2,003)	(18,766)	(22,797)
Financial expenses	(290)	(330)	(9,535)	(11,583)

The Company has no potential recoverable PIS/Pasep and COFINS embedded in the lease consideration.

15. SUPPLIERS

The amounts recorded as suppliers are mainly represented by balances payable to domestic suppliers of medicine, medical services and sundry suppliers. These medicines are used in oncological and hospital procedures.

16. SUPPLIERS DRAWEE RISK

	Consolidated	
	03/31/2023	12/31/2022
Suppliers - drawee risk	-	190,767
Cost to be amortized	-	(6,986)
Total	-	183,781

As of March 31, 2023, the Company did not have outstanding amounts. Changes in these transitions during the period ended March 31, 2023 is as follows:

	Consolidated
Balance at December 31, 2022	183,781
Payments	(190,767)
Interest incurred	6,986
Balance at March 31, 2023	-

The amount referring to the payment of principal is being presented in the statements of cash flows, in the financing line. Other information about this transaction is disclosed in Note 16 of the annual financial statements for the year ended December 31, 2022

The Company's Management also considered the guidance of CVM SNC/SEP 01/2021 Official Letter, following the qualitative aspects on this topic and concluded that there are no material impacts and that it does not significantly affect the Company's leverage.

Below is the stratification, by maturity:

	Consolidated	
	03/31/2023	12/31/2022
31–90 days	-	190,767
Total	-	190,767

17. LOANS AND FINANCING

The amounts recorded as loans and financing are stated as follows:

Description	Index Interest	Final maturities	Parent Company		Consolidated	
			03/31/2023	12/31/2022	03/31/2023	12/31/2022
Financing	IPCA + 1–1.96% p.a. 5–11.48% p.a.	04/15/2030	-	-	64,296	70,608
CCB / Working capital	CDI + 1.9–4.98% p.a. 7.956–14.71% p.a. TFC + 2.01% p.a.	07/02/2029	-	-	710,523	723,248
CRI (i)	CDI + 1.16–1.30% p.a.	08/15/2032	499,110	504,500	499,110	504,500
Law 4131	CDI + 1.73–2% p.a.	08/05/2024	-	-	366,771	6,702
FINEP (ii)	TJLP + 0.5% p.a.	12/15/2031	55,253	55,121	55,253	55,121
			<u>554,363</u>	<u>559,621</u>	<u>1,695,953</u>	<u>1,360,179</u>

Current	18,695	22,316	367,761	321,580
Non-current	535,668	537,305	1,328,192	1,038,599

- (i) On September 6, 2022, the Company carried out the 1st issue of CRI (Certificate of Real Estate Receivables), backed by unsecured non-convertible debentures, with an additional personal guarantee. 500,000 debentures were issued, with a nominal unit value of R\$ 1,000, in the total amount of R\$ 500,000.

The emission occurred in series of 3 communicating vessels, as follows: (i) the first series maturing in August 2027; (ii) the second series maturing in August 2029 and: (iii) the third series maturing in August 2032. The remuneration of these securities is as follows:

- For the first series, the corresponding remuneration interest will be 100% CDI + 1.25%.
- For the second series, interest corresponding to IPCA +6.50% p.a.; this obligation was converted by index derivative instrument (swap) to CDI + 1.16%.
- For the third series, interest corresponding to IPCA +6.65% p.a.; this obligation was converted by index derivative instrument (swap) to CDI + 1.30%.

The issue is guaranteed by its investee, Centro de Tratamento Oncológico S.A. – CTO.

- (ii) The Company has a financing agreement with FINEP in the total amount of R\$ 93,462, of which only R\$ 54,950 of principal had already been released to the Company.

As of March 31, 2023, the Group follows the non-financial and financial covenants of the group's loans and financing, which are measured annually.

Derivative instruments – swap	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Current and non-current assets	2,024	-	2,024	-
Current and non-current liabilities	-	10,113	631	11,142
Total loans, financing and debt securities, net of swaps	552,339	569,734	1,694,560	1,371,321

The Company contracted “swaps” to hedge fluctuations in price index fluctuations at the same time the CRI was raised and a Working Capital operation with Banco Santander was made, with the same terms as the issue. Adjustments to market value of swaps are presented in the balance sheet under “derivative financial instruments”. As of March 31, 2023, the weighted average cost of Swaps is approximately 100% of the CDI rate + 1.35% p.a. The asset and liability position are disclosed in Note 30.

Loan and financing settlement flow is as follows:

Settlement flow	Parent Company	Consolidated
2023	17,049	303,532
2024	6,415	406,703
2025	6,415	395,457
2026	6,415	43,182
2027	240,758	256,412
>2028	277,311	290,667
	554,363	1,695,953

Changes in loan and financing balances, for the periods ending March 31, 2023 and March 31, 2022, for the Group are presented below:

	Parent Company	Consolidated
Balance at December 31, 2021	110,649	1,158,497
New companies	-	44,789
Additions	-	69,660
Interest incurred	2,543	37,860
Payment of principal	(35,000)	(143,588)
Transfer of financial instrument – swap	-	(12,650)
Exchange-rate change	-	(498)
MTM	-	221
Payment of financial charges	(2,694)	(25,287)
Other	-	-
Balance at March 31, 2022	75,498	1,129,004
Balance at December 31, 2022	559,621	1,360,179
New companies	-	1,839
Additions	-	391,709
Interest incurred	18,911	48,865
Payment of principal	-	(47,366)
Exchange-rate change	-	(2,357)
Payment of financial charges	(24,169)	(56,916)
Balance at March 31, 2023	554,363	1,695,953

The Company has credit facilities with banks for use in working capital management, acquisition of hospital equipment for the Oncoclínicas Group's clinics, construction works in Group's clinics and acquisition of new clinics.

Oncoclínicas Group's exposure to interest rate risks and the sensitivity analysis for loans and financing are disclosed in Note 30.

18. DEBENTURES

See below the breakdown of the debenture balances for the three-month period ended March 31, 2023 and for the year ended December 31, 2022 of the Group:

	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Debentures	774,656	746,260	1,791,680	1,745,163
Total	774,656	746,260	1,791,680	1,745,163
Current	35,608	7,771	60,177	17,245
Non-current	739,048	738,489	1,731,503	1,727,918

Changes in debenture balances as of March 31, 2023 and March 31, 2022 are as follows:

	Parent Company	Consolidated
Balance at December 31, 2021	-	999,646
Debtenture cost	-	(5,398)
Interest incurred	-	30,149
Payment of financial charges	-	(14,560)
Balance at March 31, 2022	-	1,009,837
Balance at December 31, 2022	746,260	1,745,163
Interest incurred	28,395	67,428
Payment of financial charges	-	(20,911)
Balance at March 31, 2023	774,655	1,791,680

Settlement flow	Parent Company	Consolidated
2023	35,608	60,177
2024	-	42,295
2025	-	281,715
2026	-	281,709
2027	620,801	897,314
>2028	118,247	228,470
Total	774,656	1,791,680

The Company is subject to certain restrictive clauses. As of March 31, 2023, the Group is in compliance with the non-financial and financial covenants of its debenture agreements, which are measured annually.

19. SOCIAL CHARGES

The amounts recorded as social charges are stated as follows:

Description	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Salaries and wages	-	-	7,814	6,818
INSS	772	2,685	10,204	11,341
FGTS (severance indemnity fund)	220	390	714	1,560
IRRF on payroll	3,879	1,801	3,098	2,711
Provision for vacation, 13 th salary and charges	14,405	10,254	58,998	45,517
Provision for profit sharing (a)	7,318	24,137	10,379	29,729
Share-based payment program (b)	1,327	776	1,327	776
Other	-	-	3,455	2,898
Total	27,921	40,043	95,989	101,350
Current	26,594	39,267	94,662	100,574
Non-current	1,327	776	1,327	776

- (a) The Oncoclínicas Group has a profit sharing program for employees according to the profit calculated each year. The annual amount payable is defined based on results and performance indicators.
- (b) Refers to taxes on the balance of the executive and employee compensation program, in the form of a share-based payment program.

20. TAX LIABILITIES

The amounts recorded as taxes payables are stated as follows:

Description	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Withholding income tax (IRRF)	529	567	5,541	3,307
ISSQN	611	444	40,355	37,177
PIS & Cofins Taxes	3,275	3,510	51,838	43,740
Federal withholdings	398	415	3,056	2,341
Taxes in installments (ii)	-	-	17,448	18,563
PERT (i)	-	-	1,991	2,434
Tax on financial operations (IOF)	3,468	2,704	4,684	4,083
Other	712	190	4,858	3,729
Total	<u>8,993</u>	<u>7,830</u>	<u>129,771</u>	<u>115,374</u>
Current	8,993	7,830	115,202	100,249
Non-current	-	-	14,569	15,125

I. Special Tax Regularization Program - PERT

In 2017, the Special Tax Regularization Program (PERT) was created for the installment payment of federal debts held by individuals or legal entities, whether public or private, within the scope of the Federal Treasury Department and/or the Treasury Attorney General's Office.

Adhesion to PERT occurred through an application made by November 14, 2017, for debts due by April 30, 2017.

In December 2021, the Brazilian Federal Revenue Service approved most of the proceedings of the Group companies and the offsetting between assets and liabilities of the respective balances was carried out, according to Note 10.

II. The taxes paid in installments are presented below:

	Consolidated	
	03/31/2023	12/31/2022
Municipal	1,192	225
Federal	16,256	18,338
	<u>17,448</u>	<u>18,563</u>

21. ACCOUNTS PAYABLE FOR ACQUISITIONS

Acquired subsidiaries	Parent Company	
	03/31/2023	12/31/2022
Unity Participações S.A.	49,361	47,979
Centro Paulista de Oncologia S.A.	37,931	37,476
Núcleo de Oncologia da Bahia S.A.	19,204	18,493
Total	106,496	103,948
Current	18,081	1,620
Non-current	88,415	102,328
Acquired subsidiaries	Consolidated	
	03/31/2023	12/31/2022
Pro Onco Centro de Tratamento Oncológico S.A.	6,182	6,061
Multihemo Serviços Médicos S.A.	64,529	64,287
Instituto Materno Infantil de Minas Gerais S.A.	52,739	52,347
Hospital de Oncologia do Méier S.A.	19,944	19,319
Ira Instituto Roberto Alvarenga Ltda.	-	285
Centro Paulista de Oncologia	37,931	37,476
CPO – Centro Paraibano de Oncologia S.A.	16,475	21,502
Núcleo de Oncologia de Sergipe S.A.	17,013	18,798
Hematológica - Clínica de Hematologia S.A.	35,231	33,265
Centro Brasileiro de Radioterapia Oncologia e Mastologia Cebrom Ltda. (CEBROM)	52,492	51,350
CTR Centro de Tratamento Radioterápico Ltda. (CTR Bueno)	14,725	14,069
Complexo Hospitalar Uberlândia S.A.	52,383	50,876
UMC Imagem Ltda. and Instituto do Coração do Triângulo Mineiro Ltda.	2,340	2,267
Unity group	49,361	47,979
CAM/CLION Group	76,806	151,792
Cemise Group	5,625	38,406
Microimagem Laboratório de Anatomia Patológica e Citopatologia Ltda.	4,460	4,470
Medsir	1,479	2,317
Itaigara Group	116,715	112,963
Clínica de Mastologia da Bahia S.A.	540	-
Aliança Instituto de Oncologia S.A. (i)	63,268	-
Onco Vida Instituto Especializado de Oncologia Clínica S.A. (ii)	34,838	-
Cardiomobile Cardiologia Móvel Ltda. (iii)	507	-
Masto – Clínica de Mastologia da Bahia S.A.	25	-
Núcleo de Oncologia da Bahia S.A. (iv)	41,579	40,038
Total	767,186	769,867
Current	177,424	305,010
Non-current	589,762	464,557

- (i) Refers to the purchase of the remaining interest in Aliança, as mentioned in Note 11.
- (ii) Refers to the purchase of the remaining interest in the company Onco Vida, as mentioned in Note 11.
- (iii) Refers to the purchase and sale agreement signed on February 2, 2023 for the acquisition of Cardiomobile, according to Note 04.
- (iv) Refers to the registration of obligations related to put options granted by minority shareholders on the shares they hold in Núcleo de Oncologia da Bahia S.A. The exercise of this option by non-controlling shareholders is subject to future events that are not fully under the control of the Group and has as a condition the continuity of the provision of medical services by the partners of Núcleo de Oncologia da Bahia S.A. The instrument is valued at the present value of redemptions in the amount of R\$ 41,579, of which R\$ 19,205 is related to put options of founding

partners to be paid by Oncoclínicas and the amount of R\$ 22,374 is related to the put option of the partners included in the acquisition of the CAM/CLION Group to be paid by Oncoclínica Centro de Tratamento Oncológico S.A.

Accounts payable for acquisitions of Companies include Purchase and Sale Agreements resulting from withholding of installments of the amount payable. These amounts incur financial charges based on the change of the 100% CDI and/or IPCA and IGP-M rates.

The Company, in certain business combination processes, established contingent consideration clauses, which were determined based on the respective fair values, whose amount is R\$ 490,624 as of March 31, 2023.

Changes in accounts payable for acquisitions are as follows:

	<u>Parent Company</u>	<u>Consolidated</u>
Balance at December 31, 2021	35,533	454,507
Additions	-	531,216
Interest incurred and change in the fair value of contingent payments	1,616	16,906
Payment of principal	(376)	(272,064)
Capitalization – Capital contribution	-	(65,277)
Payment of financial charges	(146)	(444)
Balance at March 31, 2022	<u>36,627</u>	<u>664,844</u>
Balance at December 31, 2022	103,948	769,867
Additions	-	127,831
Price adjustment (i)	-	54
Interest incurred	455	9,729
Call options	-	492
Adjustment to present value (ii)	1,382	2,820
Adjustment to fair value (ii)	712	5,839
Payment of principal	-	(142,506)
Interest payment	-	(6,940)
Balance at March 31, 2023	<u><u>106,496</u></u>	<u><u>767,186</u></u>

- (i) Referring to price adjustment clauses based on the companies' indebtedness on the acquisition date as part of the consideration offered and adjustment to fair value of considerations contingent on combinations completed the Purchase Price Allocation in 2022.
- (ii) Refers to adjustment to present value and adjustment to fair value of considerations assumed in business combinations.

<u>Settlement flow</u>	<u>Parent Company</u>	<u>Consolidated</u>
2023	17,298	148,116
2024	37,606	141,837
2025	18,982	200,510
2026	32,610	196,421
2027	-	7,706
>2028	-	72,596
	<u>106,496</u>	<u>767,186</u>

22. OTHER LIABILITIES

Description	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Business law (b)	22,181	18,962	95,936	61,008
Redemption of preferred shares payable	113	113	15,228	24,324
Casa de Saúde São José – CSSJ partnership	-	-	21,617	21,617
Liabilities payable - Fundação Ary	3,497	3,589	3,497	3,589
Dana Farber (a)	53,834	59,989	53,834	59,989
Royalties payable	67	67	67	67
Vision Med partnership	12,793	12,467	12,793	12,467
Other accounts payable	7,457	10,240	11,431	15,228
Total	99,942	105,427	214,403	198,289
Current	52,351	53,960	144,764	127,047
Non-current	47,591	51,467	69,639	71,242

- a) Balance payable referring to the intangible assets recognized pursuant to the contract with Dana Farber Institute. The obligation payable related to this agreement is R\$ 93,533 with a discount to present value of R\$ 26,290, resulting in the net record of R\$ 67,243. In the period ended March 31, 2023, a payment of R\$ 4,723 was made, with a positive exchange-rate change of R\$ 2,182 and amortization of the APV of R\$ 750.
- (b) Balance payable referring to the exclusivity right of medical services, whose purpose is to maintain the staff of professionals with excellence in medical services and market reference. Salaries are paid monthly, according to the provision of services performed during the contractual term. The average term of contracts is 5 years.

23. PROVISION FOR TAX, LABOR AND CIVIL RISKS

The Oncoclínicas Group records provisions to face its potential liabilities. Based on information from its legal advisors, on the analysis of these issues and considering the likelihood of loss in each lawsuit, a provision was formed, which is considered sufficient to cover possible losses for which cash outflows are likely.

The provision for risks was as follows:

	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Civil	-	59	21,509	21,429
Tax	-	-	23,333	26,612
Labor	26	23	15,636	13,577
	26	82	60,478	61,618

Civil provision is mostly related to indemnity pain and suffering and property damages claimed by patients as a result of the provision of services.

The tax provision is composed of judicial and administrative discussions on the correct ISS rate that should have been used in the provision of services carried out in the municipalities of Salvador and Rio de Janeiro in a period prior to 2014, in addition to tax foreclosures aimed at charging the PIS and COFINS for the period prior to 2007.

Provision of a labor nature arises mainly from employee complaints, mostly related to claims for unhealthy work premiums, overtime claims and third-party lawsuits requesting a subsidiary conviction.

The Group recorded an amount of R\$ 35,481 referring to lawsuits related to the business combination, whose respective triggering events are prior to the acquisition date of said subsidiary by the Oncoclínicas Group. The total amount of said claims is payable by the sellers to the Group and, therefore, the recognition of this amount was made against the indemnity asset during the measurement period, as provided for by IFRS 3/CPC 15 (see note 10).

	<u>Parent Company</u>	<u>Consolidated</u>
Balance at December 31, 2021	1,068	41,134
New companies	-	8,809
Restatement of indemnifiable asset	-	947
Reversal of provision	(618)	(952)
Formations	724	4,604
Balance at March 31, 2022	<u>1,174</u>	<u>54,542</u>
Balance at December 31, 2022	<u>82</u>	<u>61,618</u>
Reversal of provision	(66)	(3,072)
Formations	10	1,932
Balance at March 31, 2023	<u><u>26</u></u>	<u><u>60,478</u></u>

The Oncoclínicas Group monitors all administrative and legal proceedings in which figures as "plaintiff" or "defendant" and backed by the opinion of its legal advisors, classifies lawsuits according to the expectation of failure. Analyses are conducted periodically on actual jurisprudential trends, and, if necessary, reclassification of the risks of these proceedings is carried out.

Possible losses, not provisioned

The Group is party to tax, civil and labor lawsuits, involving loss risks classified as possible by Management, based on the evaluation of its legal advisors. No provision was recorded as the breakdown and estimate below:

	<u>Consolidated</u>	
	<u>03/31/2023</u>	<u>12/31/2022</u>
Civil (i)	36,024	34,925
Labor (ii)	5,829	3,961
Tax (iii)	5,132	5,132
	<u><u>46,985</u></u>	<u><u>44,018</u></u>

- (i) Civil provision is mostly related to indemnity pain and suffering and property damages claimed by patients as a result of the provision of services. There is no individually relevant lawsuit.
- (ii) Provision of a labor nature arises mainly from employee complaints, mostly related to claims for unhealthy work premiums, overtime claims and third-party lawsuits requesting a subsidiary conviction. There is no individually relevant lawsuit.
- (iii) The contingencies are composed of a judicial discussion about the correct ISS rate that should have been applied to the provision of services performed in the period prior to 2007 in the city of Salvador, as well as administrative proceedings, such as a tax assessment notice drawn up by the Brazilian Federal Revenue Service alleging incorrect tax classification of imported product, generating the additional charge of IPI, PIS, COFINS import and regulatory fine, notification about the lack of withholding ISS on services taken in the Municipality of Nova Lima and Manifestations of non-compliance requesting the full approval of requests for refund arising overpayment of IRPJ/CSLL-Deemed Profit and PIS/COFINS withholding debts.

Considering the complexities of the lawsuits, as well as the Brazilian legal system, the Company is not able to estimate with reasonable accuracy the term of the decision and whether there will be any disbursement related to these lawsuits.

As of March 31, 2023 and December 31, 2022, judicial deposits are stated as follows:

	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
Civil	-	-	1	1
Labor	-	-	6,534	6,285
Tax	7,565	7,578	12,907	12,136
	<u>7,565</u>	<u>7,578</u>	<u>19,443</u>	<u>18,422</u>

The Company made judicial deposits that are restated based on the Selic rate as of the effective date of the deposit. The amount of R\$ 19,443, including legal disputes related to tax and labor matters, in which we highlight the following deposits: (i) recovery of the ICMS credit on the import of surgical equipment in the amount of R\$ 7,850 and (ii) several judicial deposits referring to ongoing labor claims.

24. SHAREHOLDERS' EQUITY

(a) Capital

As of March 31, 2023, Company's capital totals R\$ 2,249,716 fully paid-up (R\$ 2,249,716 as of December 31, 2022) represented by 494,939,864 common shares (494,939,864 common shares as of December 31, 2022).

As of March 31, 2023, the shareholding structure is comprised of:

Shareholder	Voting capital	Common shares
Goldman Sachs	62.10%	307,368,122
Bruno Ferrari	3.68%	18,199,982
Management	1.05%	5,209,476
Treasury	3.77%	18,678,889
Free Float	29.39%	145,483,395
	<u>100.00%</u>	<u>494,939,864</u>

b) Treasury shares

The Company has a share buyback program, duly approved at a Board of Directors meeting held on July 6, 2022, for the repurchase of up to 14,000,000 common shares issued by the Company, subject to the legal limit.

During the three-month period ended March 31, 2023 the repurchase transactions of 1,950,000 common shares for R\$ 14,057 occurred.

As of December 31, 2023, treasury shares totaled 18,678,889 common shares in the amount of R\$ 93,453, as shown below:

	Unit price	Number of shares	Total
Balance at December 31, 2022	<u>4.74604</u>	<u>16,728,889</u>	<u>79,396</u>
Repurchase of shares (average value)	7.20087	1,950,000	14,057
Balance at March 31, 2023	<u>5.00313</u>	<u>18,678,889</u>	<u>93,453</u>

c) Share-based payment

The Company has an executive/employee compensation program that consists of granting rights to share appreciation ("Stock Options").

The Stock Option Plan establishes the terms and conditions for the granting of common shares issued by the Company, subject to certain conditions, to the administrators, employees and service providers of the Company, or of other companies under its control.

For measurement and recognition purposes, the Company accessed the criteria established by CPC 10(R1)/IFRS 2 considering the program as an equity settlement, with the balance held in liabilities arising from tax and social security obligations that will be paid by the Company in cash.

In January 2023, the Company granted a total of 17,485,000 in new contracts with vesting of option as of 2024.

The Company recognized in the shareholders' equity, in the amount of R\$ 7,369 as of March 31, 2023 (R\$ 4,261 as of March 31, 2022).

During the first quarter of 2023, there were no cancellations of grants granted

d) Transactions with partners

In January 2023, the percentage of non-controlling interests in Aliança and Onco Vida was acquired, as mentioned in note 11, in which the effect on controlling shareholders' equity was R\$ 110,677 and for non-controlling shareholders' equity the amount was R\$ 7,754.

Other transactions in the period had an effect of R\$ 1,324 for controlling shareholders' equity and R\$ 1,468 for non-controlling shareholders' equity.

e) Capital increase

In 2023, Talassa Oncologia e Participações S.A. had a capital increase in the amount of R\$ 3,126.

f) Policy on distribution of dividends and interest on own capital (JSCP)

The dividend distribution policy complies with the provisions in the Brazilian Corporate Law, which provides for annual distribution; the Company can also, as decided by the Board of Directors, prepare semiannual, quarterly or monthly balance sheet and declare dividends out of the earnings recognized in these balance sheets. Additionally, the Board of Directors may declare interim dividends based on profit reserves recorded in the last annual or six-month period balance sheet.

In accordance with Company's bylaws, shareholders are assured a minimum dividend equivalent to 25% of net income for the year. As of December 31, 2022, Oncoclínicas do Brasil S.A. has accumulated losses, with no distribution of dividends and interest on equity to its shareholders.

As of March 31, 2023, the Company has a total provision of R\$ 46,432 (R\$ 47,091 as of December 31, 2022) payable to non-controlling interests.

25. REVENUES

The reconciliation between gross sales and net revenue is as follows:

Description	Parent Company	
	03/31/2023	03/31/2022
Gross revenue:		
Health services	58,807	48,113
Sales taxes and other deductions:		
PIS on sales	(375)	(306)
COFINS on sales	(1,730)	(1,411)
ISS on sales	(1,731)	(1,436)
Provision for expected credit loss and disallowance	(169)	(438)
	<u>(4,005)</u>	<u>(3,591)</u>
Net revenue	<u>54,802</u>	<u>44,522</u>
Description	Consolidated	
	03/31/2023	03/31/2022
Gross revenue:		
Health services	1,395,595	879,387
Sales taxes and other deductions:		
PIS on sales	(8,650)	(5,549)
COFINS on sales	(40,103)	(25,576)
ISS on sales	(34,736)	(21,846)
Provision for expected credit loss and disallowance	(18,647)	(18,464)
	<u>(102,136)</u>	<u>(71,435)</u>
Net revenue	<u>1,293,459</u>	<u>807,952</u>

Gross revenue includes revenue to be billed referring to services provided but not billed to healthcare insurance companies. These services are recognized in income (loss) based on the stage of completion of the service rendered on the reporting date of financial statements, and its contra entry is recorded in trade accounts receivable.

The concentration of the Company's net revenue is distributed in such a way that, in the three-month period ended March 31, 2023, only one customer concentrated a share greater than 16% of net revenue and all other customers, if analyzed individually, were responsible for volumes below 10% of the Company's total net revenue. Furthermore, the two customers with the highest concentration combined account for less than 30% of the Company's total net revenue.

26. COSTS AND EXPENSES BY TYPE

	Parent Company	
	03/31/2023	03/31/2022
Medical and medication costs	(37,190)	(30,281)
Personnel and charges	(49,273)	(43,681)
Expenses with "Phantom Shares" stock plan	(7,920)	(5,287)
Outsourced services	(15,282)	(21,877)
Rent and condominium	(433)	-
Infrastructure	(813)	(1,263)
Traveling	(1,269)	(1,322)
Use and consumption	(349)	(306)
Communication	(1,602)	(703)
Depreciation and amortization	(10,472)	(5,713)
Apportionment of expenses (i)	66,455	53,461
Provision to tax, labor, civil risks	56	(106)
Other revenues (expenses), net	(3,203)	(3,234)
	<u>(61,295)</u>	<u>(60,312)</u>
Costs of services rendered	(38,973)	(32,205)
General and administrative expenses	(22,637)	(28,790)
Other operating revenues (expenses)	315	683
Total	<u>(61,295)</u>	<u>(60,312)</u>
	Consolidated	
	03/31/2023	03/31/2022
Medical and medication costs	(736,539)	(482,441)
Personnel and charges	(181,517)	(117,389)
Expenses with "Phantom Shares" stock plan	(7,920)	(5,287)
Outsourced services	(58,319)	(54,910)
Rent and condominium	(4,597)	(5,897)
Infrastructure	(14,420)	(10,371)
Traveling	(3,403)	(2,955)
Use and consumption	(8,678)	(4,585)
Communication	(3,443)	(1,827)
Depreciation and amortization	(60,250)	(34,980)
Write-off of property, plant and equipment	(308)	(29)
Provision to tax, labor, civil risks	1,140	(2,026)
Other revenues (expenses), net	(6,487)	(12,719)
	<u>1,084,811</u>	<u>(735,381)</u>
Costs of services rendered	(822,914)	(536,621)
General and administrative expenses	(271,237)	(200,404)
Other operating revenues (expenses), net	9,340	1,644
Total	<u>1,084,811</u>	<u>(735,381)</u>

- i. Apportionment: this is the apportionment of costs and expenses of the Oncoclínicas Group's shared service center, centralized in the Parent Company and apportioned to its subsidiaries, according to criteria defined by management.

27. FINANCIAL INCOME (LOSS)

	Parent Company	
	03/31/2023	03/31/2022
Financial revenues:		
Yields from interest earning bank deposits	12,828	12,076
Discounts obtained	135	6
Asset interest on loans with related parties	6,820	1,110
Derivative financial instrument (liabilities) ("swap")	5,125	-
PIS and COFINS on financial revenue	(934)	(620)
Other financial revenues	4,141	145
	<u>28,115</u>	<u>12,717</u>
Financial expenses:		
Expenses with interest on loans and financing	(18,911)	(2,543)
Interest on debenture expenses	(28,395)	-
Tax on financial operations (IOF)	(1,623)	(166)
Interest expenses on accounts payable for acquisitions	(455)	(1,613)
Bank fees	(107)	(89)
Discounts granted	(6)	(3)
Interest on liabilities from loan with related parties	(13,534)	-
Derivative financial liability instrument ("swap")	(1,855)	-
Interest on lease liabilities	(290)	(501)
Adjustment to present value of financial liabilities	(1,709)	-
Adjustment to fair value of financial liabilities	(712)	-
Other financial expenses	(5,630)	(931)
	<u>(73,227)</u>	<u>(5,846)</u>
Financial income (loss)	<u>(45,112)</u>	<u>6,871</u>
	Consolidated	
	03/31/2023	03/31/2022
Financial revenues:		
Yields from interest earning bank deposits	21,554	40,142
Discounts obtained	1,643	202
Asset interest on loan with related parties	5,016	514
Derivative financial instrument (liabilities) ("swap")	6,536	-
PIS and COFINS on financial revenue	(2,582)	(2,532)
Other financial revenues	9,769	3,185
	<u>41,936</u>	<u>41,511</u>
Expenses with interest on loans		
Expenses with interest on loans	(48,865)	(37,860)
Interest on debenture expenses	(67,428)	(30,149)
Tax on financial operations (IOF)	(4,499)	(970)
Interest expenses on accounts payable for acquisitions	(9,729)	(16,906)
Bank fees	(471)	(311)
Discounts granted	(428)	(178)
Derivative financial liability instrument ("swap")	(5,818)	(221)
Interest on lease liabilities	(9,535)	(4,864)
Adjustment to present value of financial liabilities	(3,564)	-
Adjustment to fair value of financial liabilities	(5,839)	-
Interest on drawee risk	(6,986)	-
Other financial expenses	(12,577)	(6,612)
	<u>(175,739)</u>	<u>(98,072)</u>
Financial income (loss)	<u>(133,803)</u>	<u>(56,560)</u>

28. EARNINGS PER SHARE

Basic earnings per share are calculated by dividing income or loss attributable to Company's shareholder, by the weighted average number of common shares issued during the period, less the common shares purchased by the Company and held as treasury shares. As of March 31, 2023, the Company has 37,629 thousand potential common shares referring to subscription warrants resulting from the business combination with the company Unity Participações, for which their exercise is not linked to contingent conditions, being considered for the basic earnings (loss) per share.

Diluted earnings per share are calculated by adjusting to weighted average quantity of outstanding common and preferred shares, assuming conversion of all common shares that would possibly provoke dilution. As of March 31, 2023 and March 31, 2022, the Company has shares for the share-based payment program, as mentioned in Note 24. Considering the net income situation calculated for the three-month period ended March 31, 2023, such instruments were considered in determining diluted earnings per share.

	<u>03/31/2023</u>	<u>03/31/2022</u>
Income (loss) attributable to controlling shareholders	22,184	(22,993)
<u>Basic earnings (losses) per share:</u>		
Weighted average number of outstanding shares and subscription warrant	515,018,567	474,784,035
Basic earnings (losses) per share - in <i>reais</i> (R\$)	<u>0.0431</u>	<u>(0.0484)</u>
<u>Diluted earnings (loss) per share:</u>		
Weighted average number of shares outstanding, subscription warrants and shares of the share-based payment program	517,176,370	474,784,035
Diluted earnings (losses) per share – in <i>reais</i> (R\$)	<u>0.0429</u>	<u>(0.0484)</u>

29. INCOME TAX AND SOCIAL CONTRIBUTION

The Company and most of its subsidiaries elect for the taxable income regime, the other subsidiaries elect for the deemed income regime.

Income tax charges are as follows:

	Consolidated	
	<u>03/31/2023</u>	<u>03/31/2022</u>
Companies electing for the deemed income (a)	6,945	8,495
Companies electing for the taxable income (b)	26,775	23,141
	<u>33,720</u>	<u>31,636</u>

(a) Income tax charges - Companies subject to deemed income regime:

	Consolidated	
	<u>03/31/2023</u>	<u>03/31/2022</u>
Revenues		
Services	81,483	133,259
Total	<u>81,483</u>	<u>133,259</u>
Income tax assumption – 8%	6,519	10,661

Social contribution assumption – 12%	9,778	15,991
Other revenues	13,064	13,695
Income tax expense	2,937	3,653
Social contribution expense	2,056	2,672
Additional (10% on the surplus)	1,952	2,170
Total income tax and social contribution expense	<u>6,945</u>	<u>8,495</u>

(b) Income tax charges - Companies subject to taxable income regime:

	Parent Company	
	03/31/2023	03/31/2022
Income (loss) before income tax and social contribution	22,184	(22,993)
Nominal rate	34%	34%
Nominal revenue (expense)	<u>(7,543)</u>	<u>7,818</u>
Adjustments to nominal expense (revenue)		
Equity in net income of subsidiaries	25,088	(4,785)
Other permanent differences, net	(292)	46
Tax credits not formed (*)	<u>(17,254)</u>	<u>(3,079)</u>
Effective expenses	<u>-</u>	<u>-</u>
Current	-	-
Deferred	-	-
	Consolidated	
	03/31/2023	03/31/2022
Income before income tax and social contribution	74,942	16,021
Nominal rate	34%	34%
Nominal expense	<u>(25,480)</u>	<u>(5,477)</u>
Adjustments to nominal expense (revenue)		
Equity in net income of subsidiaries	33	-
Other permanent differences, net	3,208	35
Write-off of tax loss and BCN	773	-
Effect of taxation of subsidiaries based on presumed income	(274)	(939)
Tax credits not formed (*)	<u>(11,979)</u>	<u>(25,285)</u>
Effective expenses	<u>(33,720)</u>	<u>(31,636)</u>
Current	(46,546)	(27,287)
Deferred	12,826	(4,349)

(*) Refers to unrecognized deferred income tax and social contribution credits due to the lack of history of taxable income in the Company and certain subsidiaries.

(c) Deferred income tax assets – consolidated

Deferred tax arising from temporary additions and exclusions, and tax loss and negative basis of social contribution, is broken down as follows:

	<u>03/31/2023</u>	<u>12/31/2022</u>
Tax loss and negative basis of social contribution	135,809	105,090
Swap	1,290	1,425
Goodwill tax benefit by downstream merger	61,697	65,555
Provision for expected credit losses and disallowance	22,531	19,224
Provision on profit sharing	2,813	2,831
Provision for suppliers and risks	6,173	5,649
Provision for bonus	194	8,625
Surplus and deficit – Hospital Marcos Moraes	1,367	1,367
Adjustment to present value and adjustment to fair value	6,623	3,918
Funding cost of loans	3,843	3,691
Lease	8,351	6,053
	<u>250,691</u>	<u>223,428</u>

Temporary additions and exclusions

The Oncoclínicas Group calculates the deferred income tax and social contribution on tax losses, negative basis of social contribution and temporary differences, under the rates of 25% and 9% respectively.

The deferred tax asset is recognized to the extent that it is probable that taxable income will be available to be realized, based on projections of profit or loss that are prepared in line with future economic scenarios, and may suffer fluctuations.

Based on projections of future taxable income and compliance with CPC 32, in 2023, the Company recognized the amount of R\$ 30,719 of deferred assets on tax losses and negative bases of social contribution, which will be reviewed at each balance sheet date and, if necessary, will be reduced to the extent that their realization is no longer likely.

The recognized tax credits are expected to be realized as shown in the following table:

Realization estimate	Parent Company		Consolidated	
	<u>03/31/2023</u>	<u>12/31/2022</u>	<u>03/31/2023</u>	<u>12/31/2022</u>
2023	-	-	65,825	81,013
2024	-	-	47,770	42,891
2025	-	-	35,406	34,489
2026	-	-	26,753	26,738
>2027	-	-	74,936	38,297
Total	<u>-</u>	<u>-</u>	<u>250,691</u>	<u>223,428</u>

30. FINANCIAL INSTRUMENTS

(a) Financial risk factors

The Oncoclínicas Group is exposed to the following financial risks: credit risk, liquidity risk and market risk. The Group's Management has full responsibility for the establishment and supervision of the Company's risk management framework.

The risk management framework of the Oncoclínicas Group was established to identify and analyze risks to which the Oncoclínicas Group is exposed, to set risk limits and appropriate controls, and to monitor risks and compliance with limits. The Oncoclínicas Group seeks to

develop, upon its training and management procedures, a discipline and control environment in which all employees are aware of their assignments and obligations.

(i) Credit risk

Credit risk is the risk of the Oncoclínicas Group incurring losses due to a client or financial instrument counterparty and resulting from failure in complying with contract obligations. The risk basically derives from balances in financial institutions (current account, interest earning bank deposits and derivative financial instruments), trade accounts receivable, accounts receivable for the disposal of equity interests, among others.

Exposure to credit risk

The book values of financial assets classified as loans and receivables represent the maximum credit exposure. The maximum credit risk exposure at the end of the three-month period ended March 31, 2023 and year ended December 31, 2022 is as follows:

	Note	Parent Company		Consolidated	
		03/31/2023	12/31/2022	03/31/2023	12/31/2022
Cash and cash equivalents	5	52,659	79,931	409,757	263,208
Securities and financial assets	6	121,998	594,116	372,907	841,738
Trade accounts receivable	7	36,118	33,262	1,631,445	1,379,614
Judicial deposits	23	7,565	7,578	19,443	18,422
Sales of ownership interest	10	19,902	19,615	21,763	21,738
Related parties	31	489,098	191,905	35,243	32,311
Total		<u>727,340</u>	<u>926,407</u>	<u>2,490,558</u>	<u>2,557,031</u>

Cash and cash equivalents, securities and derivative financial instruments

Balances held in current accounts, interest earning bank deposits, securities and derivative financial instruments represent the maximum exposure to the credit risk of these balances. These balances are held at prime bank and financial institutions with risk rating by agencies such as Fitch, Standard & Poor's and Moody's above AA.

Trade accounts receivable

The Oncoclínicas Group's exposure to credit risks is influenced mainly by the individual characteristics of each client/health care plan. However, Management considers the history of each customer in its analysis, based on the default risk.

The management of this risk is carried out to guarantee the total receipt of revenue from agreements. The risk is mitigated by the widespread customer portfolio and the possibility of discontinuance of services to the beneficiaries of health insurance plans after a given default period.

Impairment losses

	Note	Consolidated	
		03/31/2023	12/31/2022
Trade accounts receivable	6	1,758,885	1,532,749
Provision for expected losses and disallowance	6	(127,440)	(153,135)
		<u>1,631,445</u>	<u>1,379,614</u>
% of provision on the balances of trade accounts receivable		<u>7.25%</u>	<u>9.99%</u>

As of March 31, 2023 and December 31, 2022, the provision for expected credit losses refers mainly to disallowances identified by health insurance plans during the year, and the low expectation of receipt according to the receivable expired period.

The assessment of the amount of past-due trade accounts receivable not subject to impairment is constantly monitored by the sales managers of each healthcare center, to identify amounts that may not be collected. In this case, an provision will be recognized at the amounts of the respective expected losses.

Other financial assets

Balances arising from amounts receivable for disposal of equity interests represent the maximum exposure to the credit risk of these balances.

(ii) Liquidity risk

Liquidity risk is the risk of the Group not having sufficient net funds to honor its financial commitments due to a time or volume mismatch between foreseen receipts and payments. The Oncoclínicas Group's approach in liquidity management is to guarantee, as much as possible, a sufficient liquidity to perform its obligations upon maturity, under normal and stress conditions, without causing unacceptable losses or with a risk of sullyng the Oncoclínicas Group's reputation.

The table below analyzes the Oncoclínicas Group's non-derivative liabilities and derivative financial liabilities which are not settled in a net basis by the Oncoclínicas Group, per maturity intervals, corresponding to remaining period of balance sheet until contract maturity date. Derivative financial liabilities are included in the analysis if their contract maturities are essential to understand cash flows. Amounts disclosed in the table are contracted undiscounted cash flows.

	Note	Accounting position 2023	Total future flow	Parent Company					
				Future payment flow					
				2023	2024	2025	2026	2027	>2028
Suppliers	15	34,533	34,533	34,533	-	-	-	-	-
Loans and financing	17	554,363	822,907	32,147	57,319	53,251	51,548	291,932	336,710
Debentures	18	774,656	1,189,962	103,396	87,108	79,243	75,934	705,747	138,534
Obligations payable - Fundação Ary	22	3,497	4,204	1,935	2,268	-	-	-	-
Exclusivity right	22	22,181	22,181	2,051	2,524	604	604	604	15,794
Dana Farber	22	53,834	79,968	3,728	9,883	9,883	11,295	11,295	33,884
Vision partnership	22	12,793	14,674	-	9,674	5,000	-	-	-
Related parties	31	354,586	400,873	-	400,873	-	-	-	-
Accounts payable for acquisitions	21	106,496	111,770	17,652	37,960	19,336	36,822	-	-
Total		1,916,939	2,681,072	195,442	607,609	167,317	176,203	1,009,578	524,922

	Note	Accounting position 2023	Total future flow	Consolidated					
				Payment flow					
				2023	2024	2025	2026	2027	>2028
Suppliers	15	531,273	531,273	531,273	-	-	-	-	-
Loans and financing	17	1,695,953	2,172,745	394,153	548,413	476,731	92,799	309,203	351,446
Derivative financial instruments	17	631	631	631	-	-	-	-	-
Debentures	18	1,791,680	2,729,309	229,918	251,577	467,372	445,010	1,059,854	275,578
Obligation payable - Fundação Ary	22	3,497	4,204	1,935	2,268	-	-	-	-
CSSJ partnership	22	21,617	21,617	21,617	-	-	-	-	-
Vision Med partnership	22	12,793	14,674	-	9,674	5,000	-	-	-
Exclusivity right	22	95,936	95,936	11,779	22,569	12,749	12,025	11,596	25,218
Redemption of shares	22	15,228	16,404	5,088	3,630	3,759	3,927	-	-

Dana Farber	22	53,834	79,968	3,728	9,883	9,883	11,295	11,295	33,884
Accounts payable for acquisitions	21	767,186	831,087	151,241	141,961	209,113	220,781	19,374	88,617
Related parties	31	3,337	3,337	3,337	-	-	-	-	-
Total		<u>4,992,965</u>	<u>6,501,185</u>	<u>1,354,700</u>	<u>989,975</u>	<u>1,184,607</u>	<u>785,837</u>	<u>1,411,322</u>	<u>774,743</u>

(i) Market risk

Cash flow or fair value risk associated to the interest rate

The Oncoclínicas Group's interest rate risk derives from long-term loans. Loans and financing issued at floating rates expose the Oncoclínicas Group to cash flow interest rate risk. Loans and financing issued at fixed rates expose the Oncoclínicas Group to fair value risk associated to interest rate. Oncoclínicas Group monitors its exposure to benchmark interest rate fluctuation, arising from debt instruments, and conducts sensitivity tests using different rates during its financial planning to ensure liquidity even during scenarios with higher interest rate fluctuation.

Sensitivity analysis of interest

Most of the Company's debt is pegged to the CDI rate (more than 90%), which floating rate risk is the main risk factor for the Company.

The sensitivity analysis of interest on loans, financing and debentures used as probable scenario (Scenario I) the benchmark rates for March 31, 2023, reported in Focus report, disclosed by the Central Bank of Brazil (<https://www.bcb.gov.br>) as of April 27, 2023. While scenarios II and III take into account an increase in this rate of 25% and 50%, respectively.

The results are as follows:

Scenarios	Probable Scenario I	Current scenario II +25%	Current scenario III +50%
CDI rate (p.a.)	9.90%	12.38%	14.85%
IGPM rate (p.a.)	4.20%	5.25%	6.30%
IPCA Rate (p.a.)	4.13%	5.16%	6.20%
TJLP	7.28%	9.10%	10.92%
Net assets and liabilities (Parent Company)			
CDI rate	1,084,920	1,111,772	1,138,623
IPCA rate	106,496	107,596	108,695
TJLP	55,252	56,258	57,264
	<u>1,246,668</u>	<u>1,275,625</u>	<u>1,304,582</u>
Net assets and liabilities (Consolidated)			
CDI rate	2,634,857	2,700,069	2,765,282
IGPM rate	696,063	703,372	710,681
IPCA rate	55,252	55,823	56,393
TJLP	53,605	54,580	55,556
	<u>3,439,777</u>	<u>3,513,844</u>	<u>3,587,912</u>
Interest revenues and expenses, net (Parent Company)			
CDI rate	47,788	48,971	50,154
IPCA rate	455	460	464
TJLP	225	229	233
	<u>48,468</u>	<u>49,659</u>	<u>50,851</u>
Interest revenues and expenses, net (Consolidated)			
CDI rate	91,849	94,122	96,395
IGPM rate	320	323	326
IPCA rate	8,742	8,832	8,922
TJLP	225	229	233
	<u>101,135</u>	<u>103,506</u>	<u>105,877</u>

The Company considers that the 25% and 50% variation represents an appropriate sensitivity considering the historical variation of the respective indicators in the period analyzed.

(iv) Currency risk

The Company mainly operates in the domestic market and its receivables and payables are almost in full denominated in domestic currency. The Company has a risk management policy, which determines that agreements that may pose currency risk and may significantly affect the Company's financial statements, must be subject to measures to hedge and mitigate such impact by Management.

In order to reduce its borrowings costs, the Company contracted loans in foreign currency. As a strategy to manage the foreign exchange risk, Oncoclínicas Group simultaneously carries out swap transactions under identical conditions in terms of amount, term and rate, swapping the exposure to exchange rate differences for the CDI fluctuation. Accordingly, the Company has no significant exposure to the foreign exchange risk

On September 6, 2022, the Company carried out the 1st issue of CRI (Certificate of Real Estate Receivables), backed by unsecured non-convertible debentures, with an additional personal guarantee. Five hundred thousand (500,000) debentures were issued, with a par value of R\$ 1, totaling R\$ 500. For the second and third series, the obligations were converted into an index derivative instrument (swap).

- Second series: IPCA + 6.50%
- Third series: CDI + 1.30%

The Company has no risk of exchange exposure, since, when contracting this loan mentioned in foreign currency, a linked swap operation was contracted.

The fair value of these financial instruments on the date of financial statements is as follows:

Description	Parent Company		Net
	Maturity bracket	Fair value	
"Swap":	09/06/2022		
Asset position	100% IPCA + 6.8269%	70,122	324
Liability position	100% CDI-CETIP + 1.30%	69,797	
"Swap":	09/06/2022		
Asset position	100% IPCA + 6.7040%	210,013	1,700
Liability position	100% CDI-CETIP + 1.16%	208,313	
Description	Hospital de Oncologia do Meier S.A.		Net
	Maturity bracket	Fair value	
"Swap":	06/15/2022		
Asset position	100% USD + 5.94%	25,147	
Liability position	100% CDI-CETIP + 1.9%	25,778	(631)
Description	Parent company – 2022		Net
	Maturity bracket	Fair value	
"Swap":	09/06/2022		
Asset position	100% IPCA + 6.8269%	69,152	
Liability position	100% CDI-CETIP + 1.30%	71,651	(2,499)

“Swap”:	09/06/2022		
Asset position	100% IPCA + 6.7040%	206,303	
Liability position	100% CDI-CETIP + 1.16%	213,916	(7,613)
<u>Hospital de Oncologia do Meier S.A. -2022</u>			
<u>Description</u>	<u>Maturity bracket</u>	<u>Fair value</u>	<u>Net</u>
“Swap”:	06/15/2022		
Asset position	100% USD + 5.94%	72,560	1,029
Liability position	100% CDI-CETIP + 1.9%	71,531	

(b) Capital management

The Company's objectives in managing its capital are to safeguard Oncoclínicas Group's business continuity capacity to offer return to shareholders and benefits to the other shareholders besides maintaining an optimal capital structure to reduce this cost.

In order to keep or adjust the capital structure, the Company may review the dividend payment policy, refund capital to the shareholders or, also, issue new shares or sell assets to reduce, for instance, the indebtedness level.

There were no changes in the Group's approach to the management of capital during the three-month period ended March 31, 2023. The Group manages capital requirements on an aggregate basis.

As of March 31, 2023 and December 31, 2022, the financial leverage ratios can be summarized as follows:

	Consolidated	
	03/31/2023	12/31/2022
Total loans and financing (Note 17)	1,695,953	1,360,179
Derivative financial instruments (Note 6)	631	11,142
Total debentures (Note 18)	1,791,680	1,745,163
Total accounts payable for acquisition (Note 21)	767,186	769,867
Less: cash and cash equivalents and securities	(782,664)	(1,104,946)
Net debt	3,472,786	2,781,405
Total shareholders' equity	2,549,483	2,632,456
Total capital (shareholders' equity + net debt)	<u>6,022,267</u>	<u>5,412,879</u>
Leverage ratio – %	58%	49%

(c) Estimate of fair value through profit or loss

Considering the nature and terms of transactions, the Company's Management believes that the book values of financial assets and financial liabilities measured at amortized cost, except for related-party balances (whose respective nature and conditions are disclosed in Note 31), as well as the balances of loans, financing and debentures, approximate their respective fair values.

Financial assets measured at fair value comprise derivative financial instruments, which measurement is based on observable market inputs (Level 2) and contingent consideration assumed in business combination (Level 3). The company uses the discounted cash flow technique at present value to measure the instrument. The main base information for measurement is revenue growth, determination of costs and expenses and the discounted rate.

(d) Financial instruments by category

		Parent Company			
Financial instruments	Measurement	Book value	Fair value	Book value	Fair value
		03/31/2023	03/31/2023	12/31/2022	12/31/2022
Cash and cash equivalents	Amortized cost	52,659	(*)	79,931	(*)
Securities and financial assets	Amortized cost	121,998	(*)	594,116	(*)
Derivative instruments - swap (assets)	Fair value (level 2)	2,024	2,024	-	--
Trade accounts receivable	Amortized cost	36,118	(*)	33,262	(*)
Judicial deposit	Amortized cost	7,565	(*)	7,578	(*)
Sales of ownership interest	Amortized cost	19,902	(*)	19,615	(*)
Related parties	Amortized cost	489,098	(*)	191,905	(*)
		<u>729,364</u>	<u>-</u>	<u>926,407</u>	<u>-</u>
Financial liabilities					
Suppliers	Amortized cost	34,533	(*)	50,589	(*)
Loans and financing	Amortized cost	554,363	490,053	559,621	582,460
Debentures	Amortized cost	774,656	764,813	746,260	(*)
Accounts payable – Fundação Ary	Amortized cost	3,497	(*)	3,589	(*)
Business law	Amortized cost	22,181	(*)	18,962	(*)
Dana Farber	Amortized cost	53,834	(*)	59,989	(*)
Vision partnership	Amortized cost	12,793	(*)	12,467	(*)
Related parties	Amortized cost	354,586	(*)	380,455	(*)
Accounts payable for acquisitions	Fair value (level 3)	106,946	106,946	86,220	86,220
Accounts payable for acquisitions	Amortized cost	-	-	17,764	-
		<u>1,916,939</u>	<u>-</u>	<u>1,935,880</u>	<u>-</u>
		Consolidated			
Financial instruments	Measurement	Book value	Fair value	Book value	Fair value
		03/31/2023	03/31/2023	12/31/2022	12/31/2022
Cash and cash equivalents	Amortized cost	409,757	(*)	263,208	(*)
Securities and financial assets	Amortized cost	372,907	(*)	841,738	(*)
Derivative instruments - swap (assets)	Fair value (level 2)	2,024	2,024	-	-
Trade accounts receivable	Amortized cost	1,631,445	(*)	1,379,614	(*)
Judicial deposit	Amortized cost	19,443	(*)	18,422	(*)
Sales of ownership interest	Amortized cost	21,763	(*)	21,738	(*)
Related parties	Amortized cost	35,243	(*)	32,311	(*)
		<u>2,492,583</u>	<u>-</u>	<u>2,557,031</u>	<u>-</u>
Financial liabilities					
Suppliers	Amortized cost	531,273	(*)	604,785	(*)
Suppliers - drawee risk	Amortized cost	-	-	183,781	(*)
Loans and financing	Amortized cost	1,695,953	1,645,035	1,360,179	1,551,573
Derivative instruments - swap (liabilities)	Fair value (level 2)	631	631	11,142	11,142
Debentures	Amortized cost	1,791,680	1,844,914	1,745,163	1,695,337
Obligation payable - Fundação Ary	Amortized cost	3,497	(*)	3,589	(*)
CSSJ partnership	Amortized cost	21,617	(*)	21,617	(*)
Hospital Felício Rocho partnership	Amortized cost	-	-	67	(*)
Redemption of shares	Amortized cost	15,228	(*)	24,324	(*)
CEON partnership	Amortized cost	-	-	-	-
Accounts payable for acquisitions	Amortized cost	276,562	(*)	370,516	(*)
Accounts payable for acquisitions	Fair value (level 3)	490,624	490,624	389,492	389,492
Exclusivity right	Amortized cost	95,936	(*)	61,008	(*)
Dana	Amortized cost	53,834	(*)	59,989	(*)
Vision partnership	Amortized cost	12,793	(*)	12,467	(*)
Related parties	Amortized cost	3,337	(*)	2,570	(*)
		<u>4,992,965</u>	<u>-</u>	<u>4,860,548</u>	<u>-</u>

(*) Except for the related-party balances, whose nature and conditions are disclosed in Note 31, the Company's Management believes that the book values of the financial assets and financial liabilities measured at amortized cost approximate their respective fair values, considering that they are adjusted by provision, present values and/or adjusted by floating market rates.

31. RELATED PARTIES

Transactions between related parties were carried out in accordance with the conditions agreed between the parties. They are mainly comprised of accounts receivable from shareholders, dividends receivable and payable, loans receivable and payable with related companies and advances for future capital increase:

- i) Transfer of funds among Group's companies (loans) Management transfers funds between group companies. Balances are partially eliminated in the consolidated. These balances are mostly adjusted by the IPCA and CDI. The remaining balance in consolidated refers to noncontrolling shareholders and has an average maturity of two years.
- ii) Apportionments: refers mainly to centralized shared services provided by the Parent Company, such as financial services (accounts receivable and accounts payable), accounting, legal, treasury, supplies, etc., which are shared among the other Group entities based on apportionment criteria that take into account the contribution of each entity for the Group's operations. Payments are made on a monthly basis and are not adjusted. These balances are substantially eliminated in consolidated financial statements.
- iii) Special Tax Regularization Program (PERT): Management decided to use part of the tax loss and negative basis of social contribution accumulated and declared by the parent company to settle the remaining balance of the consolidated debts, transferring the credits included in the program to subsidiaries of the same economic group. The deadline for realization of the balance is the ratification of credits and debits by the Brazilian Federal Revenue Service. These balances are eliminated in consolidated financial statements.

31.1. Related parties (Assets)

Assets	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
<u>Loans (i)</u>				
Related companies:				
Centro Paulista de Oncologia S.A.	-	-	973	973
Núcleo de Oncologia da Bahia (NOB) (i.a)	156,819	67,547	-	-
Oncoclínicas Centro de Tratamento Oncológico (i.b)	52,737	-	-	-
Cruz Participações Ltda. (Talassa)	2,620	2,521	-	-
Centro Mineiro de Infusões S.A.	1,000	1,000	-	-
CGS Faria Lima	744	710	-	-
Centro de Excelência Oncológica (i.b)	34,975	-	-	-
JHSL Consultoria S.A.	2,273	2,182	-	-
Núcleo de Hematologia e Transplante	-	-	111	111
Pontus Participações Ltda.	465	465	-	-
RT Portugal	502	-	-	-
Núcleo de Oncologia de Sergipe S.A. (i.b)	1,326	-	-	-
Oncoclínicas Rio de Janeiro S.A. – CTTB (i.b)	17,710	-	-	-
Instituto Materno Infantil de Minas Gerais S.A. (i.b)	7,190	-	-	-
Ira Instituto Roberto Alvarenga Ltda. (i.b)	809	-	-	-
Complexo Hospitalar Uberlândia S.A. (i.b)	10,395	-	-	-
UMC Imagem Ltda. (i.b)	703	-	-	-
Núcleo de Hematologia e Transplante Óssea de MG Ltda. (i.b)	2,310	-	-	-
Itaigara Memorial Hospital Dia Ltda. (i.b)	1,478	-	-	-
Instituto Oncoclínicas de Ensino (i.b)	2,126	-	2,126	-
CLION – Clínica de Oncologia Ltda. (i.b)	1,305	-	-	-
CAM – Clínica de Assistência à Mulher Ltda. (i.b)	5,465	-	-	-
ICB (i.b)	16,174	-	-	-

	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
<u>Assets</u>				
<u>Loans (i)</u>				
Related companies:				
Cettro (i.b)	14,017	-	-	-
Non-controlling shareholders (i.c)	32,033	31,227	32,033	31,227
Total loans (a)	365,177	105,652	35,243	32,311
	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
<u>Apportionments (ii)</u>				
Nature:				
Shared service center	106,181	69,421	-	-
Work Project Units	9,162	8,254	-	-
Other	4,469	4,471	-	-
Total apportionments (b)	119,813	82,146	-	-
	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
<u>PERT – Special Tax Regularization Program (iii)</u>				
Related companies:				
Centro Tratamento Oncológico S.A.	2,454	2,454	-	-
Núcleo de Oncologia de Sergipe S.A.	107	107	-	-
Radioterapia Botafogo S.A.	267	267	-	-
Centro de Quimioterapia Oncoclínicas	241	241	-	-
Centro Capixaba de Oncologia S.A.	80	80	-	-
Hematológica Clínica de Hematologia S.A.	958	958	-	-
Total PERT (c)	4,107	4,107	-	-
Total (a) + (b) + (c)	489,098	191,905	35,243	32,311

- i.a. Refers to loan operations with Núcleo de Oncologia da Bahia S.A. (NOB), which are adjusted monthly by the CDI. Loan contracts have an average term of 2 years and can be settled before maturity.
- i.b. Refers to loan operations between the Company and its direct and indirect investees, which are monthly restated by the CDI + 1.9% p.a., maturing in March 2025.
- i.c. Balances with non-controlling shareholders are restated monthly by the CDI + 2.96% p.a. and have a maturity date of August 2023.

31.2. Dividends receivable – parent company

	Parent Company	
	03/31/2023	12/31/2022
<u>Dividends receivable</u>		
Related companies:		
CPO SP	4,626	4,626
Centro Mineiro de Infusões S.A.	8,306	8,306
Oncoclínicas Salvador S.A.	329	329
Centro de Tratamento Oncológico S.A.	9,175	9,175
Oncocentro Imagem Serviços Médicos Ltda.	8,342	8,342
Oncopar Sul Empreendimentos e Participações Ltda.	1,406	1,406
Centro Brasileiro de Radioterapia Oncologia e Mastologia Cebrom Ltda. (Cebrom)	1,753	1,753
Oncologia Participações Ltda.	139	139
Hematológica - Clínica de Hematologia S.A.	2,776	2,776
Navarra RJ (Leste Fluminense S.A.)	4,271	4,271
CPO – Centro Paraibano de Oncologia S.A.	276	276
Instituto de Oncologia de Ribeirão Preto S.A.	21	21
	41,420	41,420

31.3. Advance for future capital increase (Assets)

	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
<u>Advance for future capital increase</u>				
Related companies:				
Oncopar Sul Empreendimentos e Participações Ltda.	360	2,655	-	-
Centro Mineiro de Infusões S.A.	28,583	-	-	-
ONCOCENTRO IMAGEM SERVICOS MEDICOS LTDA.	2,446	2,317	-	-
Oncologia Participações Ltda.	-	37	-	-
Oncobio Serviços de Saúde S.A.	8,900	2,300	-	-
Oncoclínica Centro de Tratamento Oncológico S.A. (CTO)	1,143	125,516	-	-
Central de Gestão e Saúde Ltda.	-	500	-	-
Idengene Medicina Diagnóstica S.A.	20,596	50,184	-	-
Oncoclínicas Participações SP Ltda.	1,130	1,200	-	-
Centro Paulista de Oncologia S.A.	-	141,778	-	-
Pontus Participações Ltda.	21,840	21,840	-	-
Locus Anat. Patol. e Citologia Ltda.	123	-	-	-
Oncologia Participações RJ ES Ltda.	690	1,300	-	-
Navarra RJ (Leste Fluminense S.A.)	6,047	-	-	-
UMC Imagem Ltda.	-	136	-	-
CTC Oncologia S.A.	20	20	-	-
Radioterapia Oncoclínicas Ribeirão Preto Ltda.	-	20	-	-
Unity	2,400	-	-	-
Total	<u>94,278</u>	<u>349,803</u>	<u>-</u>	<u>-</u>

31.4. Related parties (Liabilities)

Liabilities	Parent Company		Consolidated	
	03/31/2023	12/31/2022	03/31/2023	12/31/2022
<u>Loans</u>				
Multihemo (i)	335,754	322,661	-	-
Centro Paulista de Oncologia (ii)	14,806	55,079	-	-
Other	-	-	2,492	-
Apportionments payable	4,026	2,715	3,337	2,570
Total	<u>354,586</u>	<u>380,455</u>	<u>5,829</u>	<u>2,570</u>

i. Refers to the loan operation with the subsidiary Multihemo Serviços Médicos S.A., restated by interest of 100% of the CDI + 1.9% p.a., maturing in July 2023.

ii. Refers to a loan agreement with CPO SP, restated by interest of 100% CDI + 1.9% p.a., maturing in July 2023.

Income (loss) from related party transactions	Parent Company		Consolidated	
	03/31/2023	03/31/2023	03/31/2023	03/31/2023
<u>Revenue</u>				
Interest on loan	6,206	1,110	31,143	11,410
<u>Expense</u>				
Expense sharing	66,465	53,461	-	-
Costs of services rendered (i.e)	326	351	4,583	2,188

(i.e) Additionally, the Group entered into service agreements with companies held by some of its administrators in the amount whose object is the provision of specific and determined medical services in one or more specialties among those developed by the professional in question, including the performance medical appointments, diagnoses, prescription and follow-up of treatments at the Company's facilities and/or partners defined by the Company.

31.5. Dividends payable

	Consolidated	
	03/31/2023	12/31/2022
<u>Dividends payable</u>		
Multihemo Serviços Médicos S.A.	1,927	1,953
Núcleo de Oncologia da Bahia S.A.	248	661
Onco Vida Instituto Especializado de Oncologia Clínica S.A.	153	153
Núcleo de Oncologia de Sergipe S.A. (NOS)	844	844
Pro Onco Centro de Tratamento Oncológico S.A.	-	145
Aliança Instituto de Oncologia S.A.	6,102	10,060
Navarra RJ (Leste Fluminense S.A.)	52	7,904
Angara Participações S.A.	9,578	1,658
Yukon Participações S.A.	1,866	571
Instituto de Oncologia de Ribeirão Preto S.A.	7,479	65
COT - Centro Oncológico do Triângulo S.A.	65	793
Oncoclínicas Participações Minas Gerais S.A.	1,658	40
Baikal Participações S.A.	793	1,866
Instituto de Hematologia e Oncologia de Curitiba S.A. – Clínica Médica	571	608
CECON – Centro Capixaba de Oncologia S.A.	14,283	229
Centro de Excelência Oncológica S.A. – CEON	608	19,516
Radiogroup Participações S.A.	205	25
Total	<u>46,432</u>	<u>47,091</u>

31.6. Advance for future capital increase (Liabilities)

	Consolidated	
	03/31/2023	12/31/2022
<u>Advance for future capital increase</u>		
Subsidiaries:		
Onco Vida Instituto Especializado de Oncologia Clínica S.A.	-	2,492
Other	3,859	3,859
Total	<u>3,859</u>	<u>6,351</u>

Management remuneration

The administrators are the key persons with authority and responsibility for planning, directing and controlling the Group's activities, including any administrator (executive or another).

During the three-month period ended March 31, 2023, management remuneration was R\$ 7,776 (R\$ 5,148 in March 2022) for short-term benefits, such as salaries, charges and other. As long-term benefits, the Company recognized expenses related to the Stock Options program in the amount of R\$ 7,105 (R\$ 2,570 on March 31, 2022). There are no other benefits granted to administrators, such as: (a) post-employment benefits (pensions, other retirement benefits, post-employment life insurance and medical care); (b) long-term benefits (license for years of service and long-term disability benefits); (c) benefits on termination of employment contract.

32. INSURANCE

The Company has insurance coverage due to the risks existing in its operations. The policy is made directly by Oncoclínicas, and the premiums and risks are covered for the Company as mentioned in the policy.

The risk and type of insurance are mentioned below, and the amounts and coverage cover the full Oncoclínicas Group.

Type	Coverage	Effectiveness
Civil liability	R\$5,000	12/14/2023
Administrative Liability D&O		
	R\$ 100,000	04/29/2023
E&O professional liability	R\$30,000	12/18/2023
Equity	R\$72,000	12/31/2023

33. TRANSACTIONS NOT AFFECTING CASH

	Note	Parent Company		Consolidated	
		03/31/2023	03/31/2022	03/31/2023	03/31/2022
Acquisitions, business combination					
Statement of cash flows					
Non-cash effect					
Amount paid on acquisitions	4	-	-	8,900	265,823
Amount of cash and cash equivalents of acquired companies	4	-	-	(650)	(18,162)
Payment upon acquisitions of business, net of cash					
Acquiree		-	-	8,250	247,661
Changes in accounts receivable		2,856	2,925	251,831	116,478
Non-cash effect					
Formation (reversal) of allowance for doubtful accounts and disallowance		170	438	18,647	18,464
Accounts receivable acquired from business combination		-	-	(1,678)	(22,667)
Offset of accounts receivable - CSSJ		-	-	-	2,974
Business combination - Change in Opening Trial Balance		-	-	21,373	-
Total changes in accounts receivable		3,026	3,363	290,173	115,249
Property, plant and equipment and intangible assets					
Changes in property, plant and equipment		(461)	(1,368)	12,103	101,863
Changes in intangible assets		4,220	5,352	71,556	481,504
Total change in property, plant and equipment and intangible assets		3,759	3,984	77,459	583,367
Depreciation of property, plant and equipment	12	2,151	2,332	19,445	17,118
Amortization of intangible assets	13	6,557	2,064	22,039	9,732
Write-off of property, plant and equipment	12	-	-	308	29
Non-cash effect					
Currency conversion of goodwill with effect on Shareholders' Equity		-	-	884	3,642
Intangible assets and exclusivity rights payable	13	(4,128)	-	(47,186)	-
Transfer	13	2,840	-	2,840	-
Other changes		-	-	(21,587)	(4,977)
Goodwill in business combination	4	-	-	(9,316)	(472,215)
Property, plant and equipment and intangible assets acquired from business combination		-	-	(798)	(88,092)
Total acquisitions of property, plant and equipment and intangible assets		11,179	8,380	44,267	48,604
Acquisition of property, plant and equipment	12	1,690	964	31,013	32,801
Acquisition of intangible assets	13	9,488	7,416	13,254	16,523
Advance for future capital increase – ASSETS					

Change in balance of advance for future capital increase - assets		(255,535)	33,428	-	(1,138)
Non-cash effect					
AFAC acquired from business combination		-	-	-	1,776
Transfer of advance for future capital increase to investment	11	344,117	-	-	-
Total effects in the statement of cash flows		88,592	33,428	-	638
Advance for future capital increase – LIABILITIES					
Change in balance of advance for future capital increase - liabilities		-	-	-	3,853
Non-cash effect					
AFAC acquired from business combination		-	-	-	(2,081)
Total effects in the statement of cash flows		-	-	-	1,772
Social charges					
Change in the balance of social charges		(12,122)	(6,770)	(5,361)	3,451
Provision – Phantom	18	(551)	(1,025)	(551)	(1,025)
Non-cash effect					
Obligations acquired from business combination	4	-	-	(102)	(5,442)
Social charges acquired from business combination – Change in Opening trial balances		-	-	(26)	-
Total effects in the statement of cash flows		(12,673)	(7,795)	(6,040)	(3,016)
Tax liabilities					
Change in the balance of taxes payable		1,163	17	19,361	8,181
Tax paid		-	-	39,316	23,668
Non-cash effect					
Taxes payable acquired in business combination	4	-	-	(69)	(12,834)
Offset of tax credits		-	-	-	2,720
Social charges acquired from business combination – Change in Opening trial balances		-	-	125	-
Total effects in the statement of cash flows		1,163	17	58,733	67
Acquisitions payable					
Change in the balance of acquisitions		2,548	(376)	(2,661)	(337,341)
Interest incurred	21	(455)	-	(9,729)	-
Adjustment to present value and fair value	21	(2,094)	-	(8,659)	-
Non-cash effect					
Cash acquired in business combinations	4	-	-	650	18,162
Call and put option	21	-	-	(492)	-
Assumed consideration	21	-	-	(127,831)	-
Price adjustment	21	-	-	(54)	-
Credit offsetting for capital increase	21	-	-	-	65,277
Total effects in the statement of cash flows		-	(376)	(148,796)	(253,902)
Payment of charges		-	-	6,940	-
Payment of acquisitions		-	-	133,606	247,661
Payment of business acquisitions, net of cash acquired		-	(376)	8,900	6,241

34. SUBSEQUENT EVENTS

On May 5, 2023, Oncoclínicas signed definitive documents for the Partnership Agreement with Santa Lúcia Group (“Partnership” and “Santa Group”) for the joint operation of the oncology activities of both companies in the Federal District. The Partnership between Oncoclínicas and Santa Group comprises a long-term (60 years) operational and commercial agreement, non-corporate, for the joint operation of outpatient and hospital cancer prevention, diagnosis and treatment activities of the two companies. Through said Partnership, Oncoclínicas and Santa Group will share the combined and future economic results in oncology, according to a proportion based on the contribution of each party to the Partnership, to be calculated upon closing of the transaction.

As a result of this transaction, both companies will operate oncology jointly in the Federal District, with a network made up of diagnostic centers, clinics and cancer centers, covering the entire line of care for cancer patients and relying on a combined infrastructure 2 imaging centers, 26 outpatient units and 4 high-complexity hospitals. Therefore, each of the companies contributes with their respective operations and competences, with no payment or cash disbursement in the context of the Partnership.

Therefore, in the case of a partnership without corporate change, the Oncoclinicas Group and the Santa Group remain with their equity structure unchanged.

The Partnership will allow Oncoclínicas, after closing the transaction, to immediately establish a network of 4 cancer centers in the Federal District, with more than 850 beds and 45 operating rooms. In 2022, Oncoclínicas assisted approximately 10,000 patients in its oncology clinics in the Federal District, who will now have an even more complete and unified service experience, at any stage of treatment, providing more agility, comfort for the patient and cost-effectiveness for healthcare plans and operators.

Closing of the transaction relies on compliance with the usual conditions for transactions of this nature, including obtaining authorization from the Administrative Council for Economic Defense (CADE).

35. APPROVAL OF INDIVIDUAL AND CONSOLIDATED FINANCIAL STATEMENTS

The issue of the Company’s financial statements was approved and authorized by the Board of Directors on May 10, 2023.